The QualityStocks Daily Thursday, May 16th, 2024

Today's Top 3 Investment Newsletters

QualityStocks(CRKN) $0.2400 +419.48%

SeriousTraders(LSDI) $1.5900 +211.76%

StockEarnings(FFIE) $1.6500 +134.04%

The QualityStocks Daily Stock List

Crown Electrokinetics (CRKN)

QualityStocks, StockEarnings, Early Bird, AwesomeStocks, Zacks, StockStreetWire, Small Cap Firm, Fierce Analyst, The Stock Dork, The Online Investor, StockWireNews, PennyStockProphet and Mega Stock Alerts reported earlier on Crown Electrokinetics (CRKN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Crown ElectroKinetics Corp (NASDAQ: CRKN) is focused on the commercialization of electrokinetic technology.

The firm has its headquarters in Corvallis, Oregon and was incorporated in 2015, on April 20th by Timothy Koch, James Douvikas and Douglas B. Croxall. Prior to its name change in October 2017, the firm was known as 3D Nanocolor Corp. The firm serves consumers in the United States.

The enterprise develops and sells optical switching film which can be applied to the surface of glass or other rigid substrates like acrylic, to control opacity electronically. The film can also be embedded between sheets of smart glass powered by solar strips. The enterprise’s electro kinetic film technology, which is derived from microfluidic and ink technology, uses nanometer-sized particles of pigments which have been charged electrically and suspended in a liquid sandwiched between substrates coated with a transparent conductor oxide film. The film enables transitions between dark and clear, which allows individuals to prevent and/or manage glare, control the tint of the skylight, block out ultraviolet rays, decrease carbon emissions, and decrease the amount of heat entering the home. The enterprise’s offerings can be applied to a range of windows, including automotive sunroofs, residential windows and skylights and commercial buildings.

The company recently entered into an agreement with Hudson Pacific Properties, which involves the installation of energy-saving smart window inserts at some of the properties Hudson owns on the West Coast. This move will not only help Hudson Pacific reduce carbon emissions and energy consumption from cooling and heating systems by at least 25%, but also bring in additional revenue to Crown Electrokinetics and help extend the company’s consumer reach.

Crown Electrokinetics (CRKN), closed Thursday's trading session at $0.24, up 419.4805%, on 3,116,165,413 volume. The average volume for the last 3 months is 59.448M and the stock's 52-week low/high is $0.0414/$12.54.

Greenwave Technology Solutions (GWAV)

QualityStocks, StockWireNews, Fierce Analyst, bullseyeoptiontrading, Tim Bohen, Small Caps and Small Cap Firm reported earlier on Greenwave Technology Solutions (GWAV), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Greenwave Technology Solutions Inc. (NASDAQ: GWAV) is a scrap recycling firm that operates metal recycling facilities.

The firm has its headquarters in Suffolk, Virginia and was incorporated in 2002. Prior to its name change in October 2021, the firm was known as MassRoots Inc. It operates as part of the waste management industry, under the industrials sector. The firm serves consumers in the United States.

The company primarily operates through its Empire Services Inc. subsidiary. Its plant growing systems are designed to be efficient and self-sustainable, consuming less water, nutrients, and energy than traditional systems, helping clients ensure less environmental impact. The company operates metal recycling facilities in North Carolina and Virginia.

The enterprise, through its twelve recycling facilities, collects, classifies, and processes raw scrap ferrous and nonferrous metals for recycling. The metals include steel, iron, lead, aluminum, copper, zinc and stainless steel. It is also involved in the sale and purchase of unprocessed and processed scrap metals to steel mills and other purchasers. The enterprise provides metal recycling services to various customers, including industrial manufacturers, large corporations, government organizations and retail customers.

The company, which recently launched another metal recycling facility in Fairmont, announced that it would be expanding into the sports facility market with the launch of Greenwave Elite Sports Facility. This move will not only extend the company’s consumer reach but also bring in additional revenues and investments into the company. This is in addition to bolstering its overall growth.

Greenwave Technology Solutions (GWAV), closed Thursday's trading session at $0.1481, up 147.6589%, on 1,933,061,307 volume. The average volume for the last 3 months is 10.209M and the stock's 52-week low/high is $0.04/$1.12.

Blue Star Foods (BSFC)

QualityStocks, The Stock Dork, The Online Investor, Schaeffer's, Penny Stocks Profile and MarketBeat reported earlier on Blue Star Foods (BSFC), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Blue Star Foods Corp. (NASDAQ: BSFC) is a global seafood firm that is engaged in the importation, packaging and sale of refrigerated pasteurized crab meat and other premium seafood products which are mainly sourced from Southeast Asia.

The firm has its headquarters in Miami, Florida and was incorporated in 1995, on May 15th by John Keeler. It operates as part of the grocery and related product merchant wholesalers’ industry. The firm has four companies in its corporate family and serves consumers around the globe.

The enterprise’s main business is the importation of red and blue swimming crab meat as well as steelhead salmon meat, mainly from China, the Philippines and Indonesia and distributing in in Canada and the United States, under different brand names. The crab meat it imports is processed in about 13 plants in Southeast Asia. The enterprise’s products include foil pouches, crab cakes, dips, toppings, stuffing, salads and crabmeat cocktails. It mainly sells its products to food service distributors, as well as to retail establishments, wholesalers and seafood distributors, under the Little Cedar Falls, Coastal Pride Fresh, Good Stuff, First Choice, Lubkin, Crab & Go Premium Seafood, Oceanica, Pacifika and the Blue Star brand names.

The company recently acquired an aquaculture system salmon farming operation known as Taste of Aquafarms. It believes that the recirculating aquaculture system is the future of the seafood industry and that this move will be sustainable over the long-term. This is in addition to creating stakeholder value and extending its consumer reach.

Blue Star Foods (BSFC), closed Thursday's trading session at $0.1383, up 114.4186%, on 173,733,968 volume. The average volume for the last 3 months is 1.377M and the stock's 52-week low/high is $0.041/$2.70.

Kaixin Auto Holdings (KXIN)

MarketClub Analysis, StockMarketWatch, QualityStocks, TradersPro, Trades Of The Day, The Street, The Stock Dork, MarketBeat and InvestorPlace reported earlier on Kaixin Auto Holdings (KXIN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Kaixin Auto Holdings (NASDAQ: KXIN) (FRA: K64) is a holding company which also operates as an investment firm. The firm’s subsidiaries operate or own used car dealerships and the company is among the main dealership networks in the premium used car segment in China.

Formerly known as CM Seven Star Acquisition Corp., Kaixin Auto Holdings is based in Beijing in the People’s Republic of China and was founded in 2015. The firm is a Renren Inc. subsidiary and focuses on car brands like Porsche, Land Rover, Mercedes-Benz, BMW and Audi.

Kaixin Auto Holdings’ operating segment is inclusive of automobile sales. Geographically speaking, the firm derives its revenue from China. However, the majority of Kaixin Auto’s revenue is generated from the automobile sales segment; the sale of used cars and fees received for the role the firm plays as a channel partner for 3rd party auto financing.

Kaixin Auto Holdings provides value-added services such as after sales services, extended warranties and insurance to its consumers. Additionally, it offers financing channels to its consumers through its collaborations with financial institutions.

Kaixin Auto Holdings recently announce its purchase agreement with Haitaoche Ltd shareholders. Haitaoche is an online retail platform that imports automobiles and with the used car market in China continuing to grow rapidly combined with this partnership, the firm’s sales are bound to increase, which will prompt further growth and good returns.

Kaixin Auto Holdings (KXIN), closed Thursday's trading session at $0.22, up 71.6069%, on 34,327,354 volume. The average volume for the last 3 months is 637,314 and the stock's 52-week low/high is $0.1061/$6.66.

Sonoma Pharmaceuticals (SNOA)

QualityStocks, StockMarketWatch, MarketClub Analysis, TradersPro, MarketBeat, The Stock Dork, StockEarnings, InvestorPlace, BUYINS.NET, AwesomeStocks and StreetInsider reported earlier on Sonoma Pharmaceuticals (SNOA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Sonoma Pharmaceuticals Inc. (NASDAQ: SNOA) (FRA: O8Z3) is a specialty pharmaceutical firm that is focused on the development and production of stabilized hypochlorous acid products for different applications, including oral care, eye care, animal health care, wound care and dermatological conditions.

The firm has its headquarters in Woodstock, Georgia and was incorporated in April 1999 by Linda Alimi and Hojabr Alimi. Prior to its name change in December 2016, the firm was known as Oculus Innovative Sciences Inc. The firm serves consumers around the globe.

The enterprise’s product portfolio is made up of a HOCl-based product dubbed Acuicyn, to help relieve inflammation and itching around the eye; SebuDerm, for relief and management of itching, pain and burning associated with seborrheic dermatitis and seborrhea; Celacyn gel, which has been developed to promote healing through the management of old and new scars; a HOCl-based prescription product dubbed Levicyn, which has been developed to manage pain, itching and burning; and an antimicrobial facial cleanser dubbed Epicyn. It also develops Lasercyn gel to manage skin irritations; an atopic dermatitis hydrogel dubbed Pediacyn; a treatment of topical mild to moderate acne dubbed Gramaderm; a HOCl-based solution known as MicrocynAH, for relief of scratches, hot spots and irritated skin in animals. In addition to this, the enterprise develops Sinudox for nasal irrigation and a surface disinfectant known as Microsafe. It generates revenue from product sales around the globe.

The firm recently announced its latest financial results, with its CEO noting that they were focused on entering new markets and commercializing new products. This will be good for the firm’s growth as well as its revenues.

Sonoma Pharmaceuticals (SNOA), closed Thursday's trading session at $0.25, up 66.6667%, on 14,026,593 volume. The average volume for the last 3 months is 2.628M and the stock's 52-week low/high is $0.1159/$1.52.

Ascent Solar Technologies (ASTI)

Profitable Trader Authority, Small Cap Firm, QualityStocks, StockEarnings, OTCPicks, Investor Ideas, PennyStocks24, Alternative Energy, Top Stock Picks, SmarTrend Newsletters, StockEgg, StreetInsider, PennyTrader Publisher, The Street, StockHotTips, PennyOmega, DrStockPick, CRWEWallStreet, CRWEPicks, CRWEFinance, BestOtc, AllPennyStocks, PennyToBuck, PennyStockVille, Promotion Stock Secrets, PennyPro, PennyInvest, Penny Invest, InvestorPlace, HotOTC, Greenbackers, FeedBlitz, CoolPennyStocks, BUYINS.NET, BullRally, MadPennyStocks, Stock Rocket Report, StockRich, Stocks That Move, Street Insider, The Online Investor, StockOodles, TopPennyStockMovers, SmallCapVoice, TopStockAnalysts, TradingMarkets, TheStockWizards.net, Wall Street Resources, InvestorsUnderground, The Momentum Traders Network, DSR News, SuperStockTips, SuperStockHunter, Beacon Equity Research, WealthMakers, Winston Small Cap, InvestorSoup, The Stock Detective, Penny Stock Pinnacle, ProTrader, Wise Alerts, Shah's Insights & Indictments, 360 Wall Street, Smartmoneytrading, Stock Market Authority, Stock News Now, Stock Preacher, Lebed.biz, Penny Stocks Finder, PHUB News, Penny Stock Craze, Stockgoodies, PCG Advisory, StockMister, Momentum Traders, Mega Stock Picks, Rick Saddler, MarketBeat and Stock Specialists reported earlier on Ascent Solar Technologies (ASTI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Ascent Solar Technologies Inc. (NASDAQ: ASTI) (FRA: A8M) is a company focused on designing, manufacturing and selling copper-indium-gallium-diselenide photovoltaic products for aerospace, defense emergency management and consumer/OEM applications.

The firm has its headquarters in Thornton, Colorado and was incorporated in 2005, on October 18th by Joseph H. Armstrong and Mohan S. Misra. It operates as part of the solar industry, under the technology sector. The firm serves consumers across the globe.

The company’s technology represents the cutting edge of flexible power which can be directly integrated into consumer products and off-grid applications, as well as other aerospace applications. Its production facility is located in Thornton, Colorado.

The enterprise is focused on integrating its PV products into high value markets, such as aerospace, satellites, near earth-orbiting vehicles, and fixed-wing unmanned aerial vehicles (UAV). It also designs and manufactures PV-integrated portable power applications for commercial and military users. The enterprise's products include XD12 USB Solar Charger, XD48 Solar Charger, WS50 Solar Blanket and bare modules. It manufactures its products by affixing a thin CIGS layer to a flexible, plastic substrate using a roll-to-roll process that permits it to fabricate its flexible PV modules in an integrated sequential operation. It uses monolithic integration techniques which enable it to form complete PV modules with inter-cell connections.

The enterprise markets and sells its products through OEMs, system integrators, distributors, retailers, and e-commerce companies.

The firm, which recently introduced options trading of its stock, is focused on revolutionizing the way solar power can be used in everyday life. This will help to better meet consumer needs and create significant value for its shareholders.

Ascent Solar Technologies (ASTI), closed Thursday's trading session at $0.172, up 56.3636%, on 46,673,840 volume. The average volume for the last 3 months is 17.52M and the stock's 52-week low/high is $0.0418/$12.91.

CYNGN Inc. (CYN)

QualityStocks, The Street, MarketClub Analysis, StreetInsider, 360 Wall Street, Money Morning, The Trading Report, The Tycoon Report, The Stock Enthusiast, Street Insider, Zacks, Money and Markets, TradingAuthority Daily, MarketBeat, InvestorPlace, INO.com Market Report, AllPennyStocks and SmarTrend Newsletters reported earlier on CYNGN Inc. (CYN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

CYNGN, Inc. (NASDAQ: CYN) is an AV (autonomous vehicle) technology firm which is engaged in the development of autonomous driving software for industrial and commercial machines.

The firm has its headquarters in Menlo Park, California and was incorporated in 2013. Prior to its name change, the firm was known as Cyanogen Inc. It operates as part of the computer systems design and related services industry, under the technology sector. The firm serves consumers in the United States.

The company’s platform uses machine learning, sensor fusion and computer vision to empower vehicles to adjust to complex environments, learn and share, which transforms them into self-driving and fully-integrated fleets of the future.

The enterprise is developing an internal tool suite and infrastructure dubbed CyngnEvolvem which facilitates machine learning and artificial intelligence training to improve models and algorithms. It also offers a simulation framework which ensures that the data gathered in the field can be applied to new releases. It also develops a customer facing tool suite for managing and monitoring autonomous vehicle fleets dubbed Cyngn Insight. This tool also aggregates and analyzes data. In addition to this, the enterprise develops a modular industrial vehicle autonomous driving software known as DriveMod.

The firm recently launched a turnkey autonomous vehicle solution known as the DriveMod Kit for the Stockchaser vehicles. This move creates opportunity for the adoption of the firm’s turnkey solutions for both new and retrofit vehicles, which will help extend its consumer reach and bring in additional revenues.

CYNGN Inc. (CYN), closed Thursday's trading session at $0.126, up 46.8531%, on 353,492,050 volume. The average volume for the last 3 months is 139,900 and the stock's 52-week low/high is $0.0672/$1.248273.

Earth Science Tech (ETST)

NetworkNewsWire, QualityStocks, StocksToBuyNow, CannabisNewsWire, SmallCapRelations, Tip.us, MissionIR, TraderPower, SeriousTraders, PoliticsAndMyPortfolio.com, Penny Stock 101, PennyStockLocks, StockRockandRoll, Penny Stock General, Juicy Penny Stocks, Wall Street Mover, Shiznit Stocks, SeeThruEquity Research, Stock Commander, StockRunway, Penny Stock Titans, Tiny Gems, InvestorPlace, TopPennyStockMovers, PennyDoctor, Monster Alerts, Wallstreet Profiler, Equity Observer, GoldminePennyStocks, Hot Stock Profits, HotStockProfits, SmallCapVoice, StockMarketIntel, King Penny Stock Fortune, Penny Stock Prodigy, Money Morning, Cannabis Financial Network News, Value Penny Stocks, OtcShortReport, OTCStars.com, Promotion Stock Secrets, Seeking Penny Stocks, RedChip, Whisper from Wall Street, Penny Stocks Profile and SmallCapGrowth reported earlier on Earth Science Tech (ETST), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Earth Science Tech, Inc. (OTCQB: ETST) is a biotech firm that is engaged in delivering bioceuticals, nutraceuticals and dietary supplements in the alternative medicines, cosmetics, supplements, nutrition, wellness and health areas across the globe.

The firm has its headquarters in Doral, Florida and was incorporated in 2010, on April 23rd. Prior to its name change in April 2014, the firm was known as Ultimate Novelty Sports Inc. It operates as a part of the pharmaceutical manufacturing industry, under the health care sector, in the biotech and pharma sub-industry. The firm has two companies in its corporate family.

The enterprise is focused on delivering dietary and nutritional supplements for treating aging, nausea, weight management, depression, memory loss, high blood pressure, seizures, inflammation, joint pain and chronic pain.

The company’s products include functional foods, homeopathies, personal care products, botanicals, herbs, minerals and vitamins, among other products. In addition, it provides CBD oil to retailers in the vaping industry as well as other cannabinoid products and also retails sport, wellness and health products. The company provides its products via the internet and in its retail store which is found in Coral Gables, Florida. It markets its products in various delivery forms and formulations, which include whole herbs, powders, sprays, creams, liquids, chewables, soft gels, tablets and capsules.

As cannabis and cannabis products are legalized for use and become more popular in different parts of the world, the company may record an increase in sales, which will bring in more revenue. Their variety of products will also help extend their consumer reach, which may in turn boost investments into the firm.

Earth Science Tech (ETST), closed Thursday's trading session at $0.2, up 42.8571%, on 538,849 volume. The average volume for the last 3 months is 649,890 and the stock's 52-week low/high is $0.0002/$0.20.

Enhabit Inc. (EHAB)

MarketBeat, InsiderTrades and FreeRealTime reported earlier on Enhabit Inc. (EHAB), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Enhabit Inc. (NYSE: EHAB) (FRA: X34) is an investment holding firm engaged in the provision of home health and hospice services.

The firm has its headquarters in Dallas, Texas and was incorporated in 1998. Prior to its name change in March 2022, the firm was known as Encompass Health Home Health Holdings. It operates as part of the medical care facilities industry, under the healthcare sector. The firm serves consumers primarily in the United States.

The company operates under the Home Health and Hospice segments. The Home Health segment offers home health services via home nursing services to adult patients in need of care while the Hospice segment provides hospice agencies.

The enterprise’s home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including Alzheimer's disease, diabetes, hypertension, arthritis, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopaedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists providing therapy services. It also provides hospice services, including pain and symptom management, palliative and dietary counselling, social worker visits, spiritual counselling, and bereavement counselling services to meet the individual physical, emotional, spiritual, and psychosocial needs of terminally ill patients and their families. The enterprise operates over 110 hospice agencies and 255 home health agencies.

The firm recently reported its latest financial results, which show decreases in its revenues. It remains committed to boosting operational efficiency and patient admissions. This will positively influence revenues into the firm while also generating additional value for its shareholders.

Enhabit Inc. (EHAB), closed Thursday's trading session at $8.35, off by 3.5797%, on 697,881 volume. The average volume for the last 3 months is 568,733 and the stock's 52-week low/high is $7.12/$14.59.

Armlogi Holding (BTOC)

We reported earlier on Armlogi Holding (BTOC), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Armlogi Holding (NASDAQ: BTOC), a U.S.-based warehousing and logistics service provider that offers a comprehensive package of supply-chain solutions related to warehouse management and order fulfillment, has released the pricing of its initial public offering. The offering is comprised of 1,600,000 shares of common stock at $5 per share, resulting in gross proceeds of $8 million for the company, before the deduction of underwriting discounts and offering expenses. According to the announcement, Armlogi Holding also granted a 45-day option to underwriters to purchase up to 240,000 additional shares of common stock to cover any overallotments. EF Hutton LLC is acting as the sole book-running manager for the offering.

To view the full press release, visit https://ibn.fm/IAH3S

About Armlogi Holding Corp.

Armlogi Holding, based in Walnut, California, is a fast-growing warehousing and logistics service provider that offers a comprehensive package of supply-chain solutions relating to warehouse management and order fulfillment. The company caters to cross-border e-commerce merchants looking to establish overseas warehouses in the U.S. market. With 10 warehouses covering approximately 1,800,000 square feet, the company offers comprehensive one-stop warehousing and logistics services. The company's warehouses are equipped with facilities and technology for handling and storing large and bulky items. For more information, please visit www.Armlogi.com.

Armlogi Holding (BTOC), closed Thursday's trading session at $5, up 8.1689%, on 190,952 volume. The average volume for the last 3 months is 25,761 and the stock's 52-week low/high is $4.1392/$6.26.

Sow Good (SOWG)

StockEarnings, QualityStocks and MarketBeat reported earlier on Sow Good (SOWG), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Sow Good (NASDAQ: SOWG), a trailblazer in the freeze dried candy and treat industry, recently announced that the underwriters of its completed public offering of common stock had purchased 180,000 shares of its common stock. The underwriters made the purchase upon full exercise of their option to purchase additional shares of common stock to cover overallotments at the initial offering price of $10.00 per unit. Including proceeds from the sale of additional shares, the offering yielded approximately $13.8 million in gross proceeds before deductions. Roth Capital Partners acted as sole book-running manager for the offering, while Craig-Hallum acted as the co-manager for the offering.

To view the full press release, visit https://ibn.fm/zp7Qe

About Sow Good Inc.

Sow Good Inc. is a trailblazing U.S.-based freeze dried candy and snack manufacturer dedicated to providing consumers with innovative and explosively flavorful freeze dried treats. Sow Good has harnessed the power of its proprietary freeze-drying technology and product-specialized manufacturing facility to transform traditional candy into a novel and exciting everyday confectionaries subcategory called freeze dried candy. Sow Good is dedicated to building a company that creates good experiences for its customers and growth for its investors and employees through its core pillars: (i) innovation; (ii) scalability; (iii) manufacturing excellence: (iv) meaningful employment opportunities; and (v) food quality standards. For more information about the company, visit www.sowginc.com.

Sow Good (SOWG), closed Thursday's trading session at $17.55, up 11.3579%, on 173,236 volume. The average volume for the last 3 months is 2.426M and the stock's 52-week low/high is $1.06/$22.00.

Mind Medicine Inc. (MNMD)

QualityStocks, InvestorPlace, Schaeffer's, MarketBeat, TradersPro, The Wealth Report, The Street, The Stock Dork, PsychedelicNewsWire, MarketClub Analysis, Daily Trade Alert, Wealth Daily and Trades Of The Day reported earlier on Mind Medicine Inc. (MNMD), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Legislators in Vermont have approved a measure that would establish a task force for psychedelic therapy. The group’s primary task would be to recommend how and whether the state should regulate legal access to psychedelic drugs such as MDMA and psilocybin. The legislation is now headed to the governor’s desk.

Last week, the senate approved amended language of the legislation, approving changes made in the house. In its present form, the legislation wouldn’t amend the legal status of any drugs. Rather, the working group would review the latest evidence and research on public-health risks and benefits of clinical psychedelic-assisted therapies and check out programs and laws of other states that have permitted psychedelic use by health-care providers in a therapeutic setting.

At the moment, psilocybin and MDMA both have breakthrough therapy status granted by the U.S. Food and Drug Administration (FDA). Additionally, recently conducted trials have demonstrated MDMA’s efficacy, putting the drug on track for possible approval by the FDA later this year.

In March, state senators approved an earlier version of the measure. These recent revisions were introduced as the bill advanced out of a house committee with a clear-cut change proposed by Representative Anne Donahue. The amendment eliminated a provision that directed that the working group offer opportunities for people with lived experiences to give their testimonies.

The change also removed the positions for members on the task force who represent the Brattleboro Retreat, a psychiatric and addiction hospital, and the Psychedelic Society of Vermont. It replaced these positions with representatives from Vermont Medical Society, a nonprofit, and the state Department of Mental Health.

In addition, the change eliminated a provision that would have directed that the task force offer possible timelines for equitable and universal access to psychedelic-assisted therapies while also assessing psychedelic criminalization in the state. As introduced originally, the bill would have legalized the possession and use of psilocybin. Legislators on the Senate and Welfare Committee removed this section during discussions and elected to focus on the therapeutic task force.

If enacted, the bill would establish an overdose prevention center that would have onsite professionals trained in overdose interventions, CPR, first aid and wound care, as well as medical evaluations to determine need for more emergency care. Vermont would also become the third state to permit the establishment of these facilities, after Minnesota and Rhode Island. Other states such as New York are also looking into similar programs that could be launched statewide.

The growing wave aimed at reforming psychedelics laws around the country is likely to be motivating start-ups such as Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) to ramp up their psychedelic drug-development programs so that they can serve a public that is yearning for novel treatments against mental-health issues and other physiological ailments with underserved medical needs.

Mind Medicine Inc. (MNMD), closed Thursday's trading session at $8.65, off by 4.6307%, on 1,055,824 volume. The average volume for the last 3 months is 3,477 and the stock's 52-week low/high is $2.41/$12.22.

The QualityStocks Company Corner

Astrotech Corp. (NASDAQ: ASTC)

The QualityStocks Daily Newsletter would like to spotlight Astrotech Corp. (NASDAQ: ASTC).

The Biden administration's move to reclassify cannabis as a less hazardous substance is anticipated to ease some of the limitations on research. However, experts caution that while the change will alleviate certain restrictions, it won't eliminate all of them. Additionally, it may not necessarily reduce the potential risks associated with cannabis or enhance users' understanding of those risks. Currently, cannabis is categorized as a Schedule I substance, indicating it is deemed to have a high abuse potential and no recognized medical value. The proposed shift by the Biden administration aims to move cannabis to Schedule III, acknowledging its medical benefits to some extent. Monte warns against overlooking the health risks associated with cannabis, despite its reclassification. He and his colleagues have observed various adverse effects in individuals, such as intoxication and cyclic vomiting syndrome, as well as psychiatric symptoms, including psychosis, leading to hospital visits. Despite the reclassification, addressing these risks requires ongoing surveillance and research efforts, which the reclassification alone may not fulfill. When the DEA finally announces its cannabis rescheduling decision, entities such as Astrotech Corp. (NASDAQ: ASTC) could see new opportunities for business as their testing equipment starts attracting more interest from the marijuana research community.

Financing amounting to $4.5 million has been availed to bolster the supply chain of hemp through the production of uniforms in Alberta, Canada. Of this amount, $3.65 million will be provided to Askiy Hemp LP by the Canadian federal government. Askiy has plans to set up an industrial plant to process industrial hemp within Elk Point. In addition, the provincial government of Alberta will inject $804,000 in Logistik Unicorp, a company that makes uniforms. It should be noted that according to statistics from the federal agency Statistics Canada, the province of Alberta takes the number-one spot in terms of hemp production across the country. Last year, approximately 55,400 acres of industrial hemp was cultivated in the entire country. Alberta accounted for approximately 20,000 acres out of this national total. It therefore makes sense for funding for a hemp value chain to be directed to this province, which grows such a large amount of the crop each year. As production of different hemp grows, companies such as Astrotech Corp. (NASDAQ: ASTC) could attract plenty of interest from Canada and beyond by those interested in the testing equipment that they manufacture.

Astrotech Corp. (NASDAQ: ASTC) is an instrumentation company that designs, manufactures and commercializes solutions. Its solutions include mass spectrometry, process controls, chemical detectors and medical disease detection.

The company was established in 1984 and, prior to 2009, was known as SPACEHAB Inc., a NASA contractor offering technology originally developed for NASA to monitor air quality on the International Space Station. When the Space Shuttle program ended, the company focused on its satellite processing and mass spectrometer instrumentation units and adopted the Astrotech name.

In 2014, Astrotech sold its satellite subsidiary to focus on its Astrotech Technology Inc. (ATi) mass spectrometry solutions, which offer a number of advantages over competing platforms. Notably, Astrotech’s ATi technology is ruggedized, rapid, simple to use and customizable, with hands-free calibration and tuning.

Between 2016 and 2019, the company secured U.S. patents for its technology and achieved European Union (ECAC) certification for the TRACER 1000™, the world’s first mass-spec Explosives Trace Detector (ETD) used in airports worldwide. Astrotech continues to innovate and add to its suite of products, including AgLAB-1000, a process control system, and the BreathTest 1000, a disease detection solution.

Astrotech is headquartered in Austin, Texas.

Subsidiaries

Astrotech Technologies Inc.

Astrotech Technologies Inc. (ATi) owns and licenses the platform mass spectrometry technology originally developed by 1st Detect. This technology is designed to be less expensive, smaller and easier to use than traditional mass spectrometers.

Unlike other technologies, ATi works under high vacuum, which eliminates competing molecules, yielding higher resolution and fewer false alarms. The company’s intellectual property includes 18 granted patents, along with extensive trade secrets.

ATi exclusively licenses the Astrotech Mass Spectrometer Technology to the three wholly owned subsidiaries of Astrotech.

1st Detect Corp.

1st Detect Corp. developed the TRACER 1000, the world’s first mass spectrometry-based explosives and narcotics trace detector. 1st Detect ETDs were developed for use at airports, cargo facilities and other secured locations and borders worldwide.

1st Detect’s commercial sales of the TRACER 1000 ETD, consumables and recurring maintenance services brought in $750,000 in total revenue during the fiscal year ended June 30, 2023. The Astrotech subsidiary recently secured two orders for a total of 24 Tracer 1000 units from two Romanian security and telecommunications companies, to be delivered during calendar 2023.

AgLAB Inc.

AgLAB Inc. is developing a series of mass spectrometers for use in the hemp and cannabis market, with an initial focus on optimizing yields in the distillation processes.

AgLAB, which uses the company’s proprietary AgLAB 1000-D2™ mass spectrometer, has been proven to improve distillation oil yields and bottom-line profits for hemp and cannabis producers. During field trials, AgLAB was able to improve ending-weight yields by an average of 24%.

BreathTech Corp.

BreathTech is developing the BreathTest-1000™, a breath analysis tool to screen for volatile organic compound (“VOC”) metabolites found in a person’s breath that could indicate they may have a compromised condition including but not limited to a bacterial or viral infection. The company believes that new tools to aid in the battle against COVID-19 and other diseases remain of the utmost importance to help more quickly identify that an infection may be present.

Market Opportunity

A report by Mordor Intelligence, a research and advisory firm, put the global mass spectrometry market at $6.37 billion in 2023. The market is forecast to grow to $8.63 billion by 2028, achieving a CAGR of 6.25% during the forecast period.

One of the major driving factors for the growth of the mass spectrometry market is technological advancements in mass spectrometer devices, the report states. Key market players are continuously working toward advancing their existing products and launching innovative and advanced mass spectrometer devices.

Another major factor that is expected to boost market growth is increasing research and development expenditure by both government and private entities, according to the report. Mass spectrometry devices are also being used in the detection and analysis of COVID-19 and other disease samples, which may have a positive impact on the market.

Management Team

The Astrotech leadership team includes management executives, as well as industry and technology experts. The company continues to actively expand its talent pool to meet evolving demands.

Thomas B. Pickens III is Chairman, CEO and Chief Technology Officer of Astrotech Corp. He also serves as CEO of Astrotech subsidiaries ATi, 1st Detect, AgLAB Inc. and BreathTech Corp. Previously, he was the founder and president of Beta Computer Systems Inc. and T.B. Pickens & Co. He was founder and general partner of Grace Pickens Acquisition Partners L.P and managing partner of Sumpter Partners. He also served as CEO of Catalyst Energy Corporation and United Thermal Corporation and as president of Golden Bear Corp., United Hydro Inc. and Slate Creek Corp. He received a B.A. in Economics, Computer Science and Engineering from Southern Methodist University.

Jaime Hinojosa, CPA, is CFO at Astrotech Corp. He joined the company in 2015 and has served as its Corporate Controller since 2019. His previous roles with the company include Director of Finance, from 2017 to 2019, and Assistant Controller, from 2015 to 2017. Prior to joining Astrotech, Mr. Hinojosa worked as an Accounting Manager for O’Reilly Auto Parts and gained public accounting experience as an Audit Manager at Burton McCumber & Cortez LLP.

Astrotech Corp. (NASDAQ: ASTC), closed Thursday's trading session at $9.5099, up 4.8501%, on 12,013 volume. The average volume for the last 3 months is 477,270 and the stock's 52-week low/high is $7.00/$15.11.

Recent News

Lexaria Bioscience Corp. (NASDAQ: LEXX)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (NASDAQ: LEXX).

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, has proven in numerous studies the ability of its patented DehydraTECH(TM) technology to increase bio-absorption compared to standard industry formulations, as well as reduce time of onset and deliver drugs more effectively across the blood-brain barrier. "DehydraTECH has a number of potential pharmaceutical applications, a testament to its versatility and overall effectiveness. The key factor that has played a role in its adoption is its unique ability to improve drug bioavailability, a critical marker and determinant of overall drug effectiveness," a recent article reads. "With this technology, Lexaria looks to tap into various growing markets, among them the cardiovascular drugs and diabetes markets, both projected to be valued at $115.8 billion and $134.1 billion by 2028 and 2030, respectively. It also hopes to make drugs more effective, possibly reducing the cost of treatment and improving the patients' overall quality of life. The company is also aggressively pushing for its patent applications and approvals globally, a show of commitment to creating shareholder value. In addition to its focus on GLP-1 clinical studies for the 2024 calendar year, Lexaria is confident that it will carve out a decent market share for itself, ultimately making 2024 its biggest year yet."

To view the full article, visit https://ibn.fm/s73Q9

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator in drug delivery platforms. The company’s patented technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules. DehydraTECH promotes fast-acting, less expensive and more effective oral drug delivery and has been thoroughly evaluated through in vivo, in vitro and human clinical testing.

DehydraTECH is covered by 21 issued and more than 50 pending patents in over 40 countries around the world. Lexaria’s first patent was issued by the U.S. Patent and Trademark Office in October 2016 (US 9,474,725 B1), providing 20 years of patent protection expiring June 2034. Multiple patents have been awarded since then and are expected in the future.

Lexaria has also collaborated with the National Research Council (NRC), the Canadian government’s premier research and technology organization. The company has been granted patent protection for specific delivery of nicotine, vitamins, NSAIDs, antiviral drugs, cannabinoids and more.

Lexaria began developing DehydraTECH in 2014 and has since continued to strengthen and broaden the technology. The company has no plans to create or sell Lexaria-branded products containing controlled substances. Instead, Lexaria licenses its technology to other companies around the world to offer consumers the best possible performance across an array of ingestible product formats.

The company’s technology is best thought of as an additional layer that providers of consumer supplements, prescription and non-prescription drugs, nicotine and CBD products can utilize to improve the effectiveness of their own existing or planned new offerings. Lexaria has licensed DehydraTECH to multiple companies, including a world-leading tobacco producer for the research and development of smokeless, oral-based nicotine products, and for use in industries that produce cannabinoid beverages, edibles and oral products.

DehydraTECH is suitable for use with a wide range of product formats including pharmaceuticals, nutraceuticals, consumer packaged goods and over-the-counter capsules, pills, tablets and oral suspensions.

DehydraTECH Technology

Lexaria’s DehydraTECH is designed specifically for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients. DehydraTECH increases their effectiveness and improves the way active pharmaceutical ingredients enter the bloodstream. The major benefits to a subject ingesting a DehydraTECH-enabled drug or consumer product can be summarized by the following:

  • Speeds up delivery – the effects of the product are felt by the subject in just minutes.
  • Increases bioavailability – the technology is much more effective at delivering a drug or product into the bloodstream.
  • Increases brain absorption – animal testing suggests significant improvement in the quantity of drug delivered across the blood-brain barrier.
  • Improves drug potency – more of the ingested product is made available to the body, so lower doses are required to achieve the desired effect.
  • Reduces drug administration cost – lower doses mean lower overall drug costs.
  • Masks unwanted taste – the technology eliminates or reduces the need for sweeteners.

Lexaria has demonstrated in animal studies a propensity for DehydraTECH technology to elevate the quantity of drug delivered across the blood-brain barrier by as much as 1,900 percent, initiating additional new patent applications and opening possibilities for improved drug delivery.

Since 2016, DehydraTECH has repeatedly demonstrated, with cannabinoids and nicotine, the ability to increase bio-absorption by up to five to 10 times, reduce time of onset from one to two hours to just minutes, and mask unwanted tastes. The technology is to be further evaluated for additional orally administered bioactive molecules, including antivirals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and nicotine.

Market Outlook

Lexaria’s ongoing research and development efforts are mainly focused on development of product candidates across several key segments:

  • Oral Cannabinoids – a market estimated to be worth $18.4 billion in 2021 and expected to reach $46.2 billion by 2025.
  • Antivirals – an estimated $52.1 billion market in 2021 that’s expected to grow to $66.7 billion by 2025.
  • Oral Mucosal Nicotine – smokeless tobacco products, a $13.6 billion market in 2018, is forecast to grow at 7.2 percent annually through 2025.
  • Human Hormones – estrogen and testosterone replacement therapies represented a $21.9 billion market in 2019, with a forecast CAGR of 7.7 percent through 2027.
  • Ibuprofen and Naproxen – NSAID sales totaled $15.6 billion globally in 2019 and are projected to reach $24.4 billion by 2027.
  • Vitamin D3 – the global market size was $1.1 billion in 2021, growing at 7 percent per year and expected to reach $1.7 billion in 2026.

Management Team

Chris Bunka is Chairman and CEO of Lexaria Bioscience Corp. He is a serial entrepreneur who has been involved in several private and public companies since the late 1980s. He has extensive experience in the capital markets, corporate governance, mergers and acquisitions, as well as corporate finance. He is named as an inventor on multiple patent innovations.

John Docherty, M.Sc., is the President of Lexaria. He is a pharmacologist and toxicologist, and a specialist in the development of drug delivery technologies. He is the former president and COO of Helix BioPharma Corp. (TSX: HBP). He is named as an inventor on multiple issued and pending patents.

Greg Downey is Lexaria’s CFO. He has more than 35 years of diverse financial experience in the mining, oil and gas, manufacturing, and construction industries, and in the public sector. He served for eight years as CFO for several public companies and has provided business advisory and financial accounting services to many large organizations.

Gregg Smith is a strategic advisor to Lexaria. He is a founder and private investor with Evolution VC Partners. He is a member of the Sand Hill Angels and held previous investment banking roles with Cowen and Company and Bank of America Merrill Lynch.

Dr. Philip Ainslie serves as a scientific and medical advisor to Lexaria. He is co-director for the Centre for Heart, Lung and Vascular Health, Canada. He is also Research Chair in Cerebrovascular Physiology and Professor at the School of Health and Exercise Sciences, Faculty of Health and Social Development at the University of British Columbia.

Lexaria Bioscience Corp. (LEXX), closed Thursday's trading session at $3.14, up 1.9481%, on 117,387 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $15.11/$.

Recent News

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI)

The QualityStocks Daily Newsletter would like to spotlight Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI).

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on the development of inflammation and immunology ("I&I") biological products and on providing contract development and manufacturing organization ("CDMO") services through its Scinai Bioservices business unit, is reporting its full-year financial results for 2023 along with a company update. Highlights of the report included news that, in the first four months of 2024, the company has received CDMO work orders valued at approximately $500,000, with current guidance for this year of approximately $1.25 million in expected revenues. The report also noted that the company is "aggressively advancing" its NanoAb preclinical development, with promising results obtained in a psoriatic human skin model and the conclusion of an in-vivo proof of concept animal study conducted in collaboration with Professor Amos Gilhar, a world-renowned dermatologist. The company is preparing for a scientific advisory meeting with the Paul Erlich Institute ("PEI") of Germany, which is considered the European comparable to a pre-IND meeting with the U.S. Food and Drug Administration in the United States. Financial numbers show R&D expensesfor FY 2023 reached $5.2 million, compared to $5.7 million for 2022, with marketing, general and administrative expensesfor the year totaling $4.5 million , compared to $5.3 million for 2022. Financial incometotaled $3.2 million with net loss of $6.5 million with the company reporting cash and cash equivalents and short-term deposits of $4.9 million.

To view the full press release, visit https://ibn.fm/msFcQ

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) is a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious diseases and autoimmune diseases.

In collaboration with the prestigious Max Planck Institute for Multidisciplinary Sciences (MPG) and the University Medical Center Göttingen (UMG), both in Germany, Scinai is developing a pipeline of innovative nanosized antibody (NanoAb) therapies addressing diseases underserved by current treatments and with large and growing markets, such as COVID-19, asthma and psoriasis.

NanoAbs, also known as VHH-antibodies or Nanobodies, are alpaca-derived nanosized antibodies that exhibit multiple significant competitive advantages over existing antibody therapies, including stability at high temperatures, superior binding affinity, more effective and convenient routes of administration and efficient production. Scinai is uniquely positioned to advance nanosized antibody innovation from R&D through commercialization.

The company’s highly experienced and successful pharmaceutical industry leadership team includes former senior executives from Novartis, GSK and Bristol-Myers Squibb.

Since its founding, Scinai has executed eight clinical trials, including a seven-country, 12,400-participant Phase 3 trial of a prior influenza vaccine candidate, and it built, owns and operates a 20,000 sq. ft. state-of-the-art GMP biologics manufacturing facility housing its laboratories, production facilities and offices.

Lead Candidate: Inhaled COVID-19 NanoAb

In December 2021, Scinai signed definitive agreements with the Max Planck Society – parent organization of the Max Planck Institute for Multidisciplinary Sciences– and the UMG to enter a strategic collaboration for the development and commercialization of innovative COVID-19 NanoAbs.

The company is planning a rapid development path that leverages its expertise and capabilities in biological drug development and manufacturing. Scinai anticipates preclinical proof-of-concept results for an inhaled COVID-19 NanoAb by the end of 2022, with initial Phase 1/2a human clinical trial results expected in 2023.

The intended inhaled mechanism of delivery of Scinai’s COVID-19 NanoAb formulation may serve as a significant differentiator when compared to approved monoclonal antibodies, which are injected. Inhaled delivery has shown to be cheaper, more convenient and likely safer for patients and providers.

NanoAb Pipeline: Psoriasis, Asthma and More

The COVID-19 NanoAb development agreement is part of a broader five-year research collaboration agreement signed in March 2022 covering discovery, development and commercialization of NanoAbs for several other disease indications with large market medical needs, including asthma, psoriasis, macular degeneration and psoriatic arthritis.

Scinai has an exclusive worldwide license for development and commercialization of COVID-19 NanoAbs and exclusive options for similar worldwide licenses for NanoAbs for the above mentioned additional large market disorders currently underserved by approved therapeutic antibodies.

Academic research teams from MPG and UMG have verified strong affinity by the new NanoAbs to their biological target molecules and high thermostability. They have also demonstrated strong neutralization by several NanoAb candidates of their respective target molecules. Neutralization studies of the other NanoAbs are expected to begin later in 2022.

Based on the promising results, Scinai will focus development efforts beginning with the following NanoAbs:

  • NanoAbs targeting IL-17 as drug candidates for the potential treatment of psoriasis and psoriatic arthritis
  • NanoAbs targeting IL-13 and NanoAbs targeting TSLP as drug candidates for the potential treatment of asthma

These are conditions for which the antibody target is validated by existing treatments and the mechanism of action is well understood. Both represent large medical needs and growing markets. Scinai anticipates preclinical proof-of-concept for at least one of these NanoAbs in 2023. This is in addition to the aforementioned human clinical Phase 1/2a for the inhaled COVID-19 NanoAb therapy, which is also anticipated in 2023.

CDMO Services

While NanoAb pipeline development is Scinai’s core focus, the company also offers its cGMP manufacturing facility, aseptic fill and finish suite, laboratories and experienced professionals for contract development and manufacturing organization (CDMO) services. This offering is designed to keep the Scinai team abreast of the latest industry developments and trends while building experience and generating revenue to support the company’s NanoAb pipeline development.

Market Opportunity

COVID-19 treatment, target of the company’s lead NanoAb therapy candidate, had an estimated market size of $22 billion in 2021.

Future Scinai drug candidates will target conditions with large markets growing at attractive CAGRs.

The global asthma treatment market was valued at $18.08 billion in 2019 and is projected to reach $26.01 billion by 2027, exhibiting a CAGR of 4.5% during the forecast period, according to Fortune Business Insights. The research firm predicts that the global psoriasis treatment market will grow from $26.37 billion in 2022 to $47.24 billion by 2029, exhibiting a CAGR of 8.7% over the forecast period.

Management Team

Amir Reichman is Scinai’s CEO. He previously was Head of Global Vaccines Engineering Core Technologies at GSK Vaccines in Belgium. Prior to that, he held leadership roles at Novartis Vaccines’ Global Vaccines Supply Chain Management organization. He was the first employee of NeuroDerm Ltd., a company focused on transdermal drug delivery, and served as Senior Scientist until his departure in 2009. He earned a M.Sc. in Biotechnology Engineering from Ben-Gurion University and an MBA in Finance and Health Care Management from the University of Pennsylvania’s Wharton School.

Tamar Ben-Yedidia, Ph.D., is Chief Science Officer at Scinai. She has more than 30 years of experience in immunology, with specific expertise in the development of vaccines. She began her career with Biotechnology General Ltd., working on development of a recombinant Hepatitis-B vaccine. She later joined the Weizmann Institute of Science, working on the design of a peptide-based vaccine against several pathogens. She is widely published, with numerous refereed articles and invited reviews in various scientific journals. She received her Ph.D. from the Weizmann Institute.

Elad Mark is COO at Scinai. He has over 15 years of biotechnology industry experience encompassing diverse project stages including feasibility studies, conceptual and detailed design, commissioning, qualification and process validation. Prior to joining Scinai, he led Novartis’s $800 million investment in a biologics facility in Singapore. With Biopharmax and Antero, both global pharmaceutical engineering companies, he successfully led projects in Israel, China and Singapore. He holds a BSc. in Engineering from the Afeka Tel Aviv Academic College of Engineering and an MBA from the Open University of Israel.

Uri Ben-Or is CFO at Scinai. He has served as CFO with public life science companies traded on the TASE, OTC and Nasdaq. Ben-Or provides his services to Scinai through CFO Direct, a company he founded and for which he serves as CEO. He served as the VP of Finance of Glycominds, a leading biotechnology company, and as CFO of a spin-off from Telrad Networks. He also served as a Corporate Controller at Menorah Capital Markets and as an Auditor at PWC. He holds a B.A. in Business from the College of Administration, an MBA from Bar-Ilan University, and is a CPA.

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), closed Thursday's trading session at $0.45, up 2.2727%, on 11,687 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.4303/$2.27.

Recent News

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, is reporting its financial and business results for the first quarter 2024, the period ended March 31, 2024. A highlight of the report was that enrollment is nearly completed in a potentially pivotal GBM study evaluating Berubicin with topline data expected in the first half of 2025. In addition, financial results showed a net loss for the quarter of approximately $3.5 million, down from an estimated $4.9 million net loss for the comparable period in 2023; R&D expenses of $2.4 million with general and administrative expense totaling an estimated $1.1 million, compared to approximately $1.4 million for the same period in 2023; and cash on hand at the end of the quarter totaling about $0.8 million. "With topline results in our ongoing, fully enrolled Berubicin trial for GBM expected in the first half of next year, we continue to plan for success," said CNS Pharmaceuticals CEO John Climaco in the press release. "Our commitment to our dual mission to bring meaningful treatment options to GBM patients as well as value to all stakeholders remains unwavering."

To view the full press release, visit https://ibn.fm/lfRkd

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (http://nnw.fm/eDUjp).

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Thursday's trading session at $0.2249, up 12.6754%, on 328,413 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.19/$2.98.

Recent News

SuperCom Ltd. (NASDAQ: SPCB)

The QualityStocks Daily Newsletter would like to spotlight SuperCom Ltd. (NASDAQ: SPCB) .

SuperCom Ltd. (NASDAQ: SPCB), a global provider of secure solutions for the e-Government, IoT, and cybersecurity sectors, today announced it had secured a new, additional contract with a long-standing government customer. According to the announcement, the contract, valued at $1.8 million, continues a successful partnership that has been in place for over a decade. The contract is expected to start by end of May 2024 and to be fulfilled within 5 months. "We are pleased to continue our partnership with a government customer who has trusted our solutions for over a decade. This contract not only signifies their satisfaction with our work but also their confidence in SuperCom's ability to consistently deliver high-quality products and services," said Ordan Trabelsi, President and CEO of SuperCom. "Our ability to secure more contracts of this magnitude with our long-term customers demonstrates our competitive edge and unwavering dedication to their success. This ongoing relationship is a testament to our commitment to excellence and our ability to meet the evolving needs of our clients across the globe."

To view the full press release, visit https://ibn.fm/DmxBn

SuperCom (NASDAQ: SPCB), a global provider of secured solutions for the e-government, IoT and cybersecurity sectors, has announced results for the three months ended March 31, 2024. Among the highlights, the company reported an 8% increase in revenue to $6.9 million from $6.4 million and 139% increase in gross profit to $3.8 million from $1.6 million compared to the first quarter of 2023. "We are pleased to report a strong start to 2024, marked by significant financial and operational achievements. This quarter, we've continued to see revenue growth YoY and a dramatic improvement in our profitability metrics leading to an eight-year-record profit," said Ordan Trabelsi, president and CEO of SuperCom. "The substantial growth in our gross profit reflects the inherent quality and high-margin potential of our key projects and our successful progression through different stages of these projects. Typically, the initial stages of these projects involve higher expenses, which subsequently give way to higher gross margins as the projects advance, as demonstrated by this quarter's results. Additionally, our EBITDA year-over-year has seen a remarkable 400% increase. This improvement is a testament to our rigorous management practices and dedication to effectively leveraging our core business infrastructure."

To view the full press release, visit https://ibn.fm/nGW2F

SuperCom Ltd. (NASDAQ: SPCB) provides secured solutions for the e-government, IoT and cybersecurity sectors. Since 1988, the company has been a trusted global provider of traditional and digital identity offerings, providing cutting-edge electronic and digital security solutions to governments and organizations, both private and public, around the world.

SuperCom’s mission is to revolutionize the public safety sector worldwide through proprietary electronic monitoring technology, data intelligence, and complementary services.

The company is headquartered in Tel Aviv, Israel, with offices in California and other regions in the U.S.

Business Units

IoT and Connectivity

SuperCom IoT products and solutions provide advanced electronic monitoring solutions and services to criminal justice agencies, enabling customers to detect unauthorized movement of people, vehicles, and other monitored objects. The company provides an all-in-one, field-proven PureSecurity offender monitoring suite, accompanied by services such as GPS monitoring, home detention, domestic violence prevention, and more. The company’s services are specifically tailored to meet each client’s needs.

SuperCom’s proprietary Puresecurity suite of hardware, connectivity, and software components is the foundation for its criminal justice services and offerings. SuperCom is leveraging its extensive technology expertise to implement groundbreaking artificial intelligence (AI) technologies into various parts of its core offerings. By leveraging the power of AI, SuperCom’s PureSecurity platform can offer new abilities, such as amplified data analysis, predictive modeling, and streamlined automation – all geared toward optimizing decision-making and operational efficiency.

Competitive advantages of SuperCom’s technology include:

  • Long Battery Life (No Tag Charging Required)
  • Ultra Lightweight Form Factor
  • Next-Gen Location Tech
  • Protection of Domestic Violence Victims
  • And More

 

Cybersecurity

In 2015, SuperCom identified the cybersecurity market as a fast-growing space with significant advantages due to synergistic technologies and a shared customer base with its e-Gov and IoT business units. Consequently, SuperCom strategically acquired Prevision Ltd., a company with a strong presence in the market and a broad range of competitive cybersecurity services.

During the first quarter of 2016, SuperCom acquired Safend Ltd., an international provider of cutting-edge endpoint data protection guarding against corporate data loss and theft through content discovery and inspection, encryption methodologies, and comprehensive device and port control.

Both acquisitions significantly expanded the breadth of the company’s global cybersecurity capabilities.

e-Gov

Through proprietary e-government platforms and innovative solutions for traditional and biometrics enrollment, personalization, issuance, and border control services, SuperCom has helped governments, and national agencies design and issue secured multi-identification, or Multi-ID, documents and robust digital identity solutions to their citizens, visitors, and lands.

The company has focused on expanding its activities in the traditional identification, or ID, and electronic identification, or e-Gov, markets, including the design, development, and marketing of identification technologies and solutions to governments in Europe, Asia, America, and Africa using SuperCom’s e-Government platforms.

Market Opportunity

Data from Berg Insight estimates the market for electronic monitoring solutions will grow from $1.2 billion in 2021 to $2.1 billion in 2026, marking a CAGR of 10.8% for the forecast period.

High recidivism rates, prison overcrowding, and soaring incarceration costs are some factors that are driving the electronic monitoring of offenders’ market growth.

An analysis by ReportLinker forecasts that the global cybersecurity market will grow from an estimated value of $173.5 billion in 2022 to $266.2 billion by 2027, achieving a CAGR of 8.9% for the period.

The increased number of data breaches worldwide, the ability of malicious actors to operate from anywhere in the world, the links between cyberspace and physical systems, and the difficulty of reducing vulnerabilities and consequences in complex cyber networks are some factors driving the cybersecurity market growth.

Management Team

Ordan Trabelsi is President and CEO of SuperCom. He has over 15 years of experience as CEO, growing high-tech companies globally. He also has experience in research and development and product innovation, as well as hands-on experience in cybersecurity, encryption, advanced mathematics, and mobile and internet network technologies. Prior to joining SuperCom, he served as co-founder and CEO of Klikot Inc., a global social networking company. He holds an MBA from Columbia University and a B.Sc. in Computer Engineering from The Technion: Israel Institute of Technology.

Barak Trabelsi is COO of SuperCom. He has expertise in big data, cyber, mobile, and internet network technologies, as well as extensive experience in product development and strategies. Prior to joining SuperCom, he served as Senior Product Manager at Equinox Ltd. Before that, he served for four years as VP of R&D at Sigma Wave, a wireless, security, and internet-focused company. He holds a B.Sc. in Computer Science and Business, as well as an MBA from Tel Aviv University.

Gil Alfi is VP of Sales at Safend Ltd., SuperCom’s cybersecurity subsidiary. He joined SuperCom in 2016 as VP of Business Development for Safend. He has more than 18 years of experience in technology companies. He served as an R&D team technology lead for more than seven years and as Director of Product Management for various telecom and wireless companies for more than 10 years. Prior to joining SuperCom, he served as Regional Sales Director at Safend, managing sales regions in Europe and Africa. He holds a B.Sc. in Computer Science and Mathematics and an M.Sc. in Computer Science from Bar-Ilan University.

SuperCom Ltd. (NASDAQ: SPCB), closed Thursday's trading session at $0.2069, up 2.7309%, on 10,230,830 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.1524/$1.27.

Recent News

Tartisan Nickel Corp. (CSE: TN) (OTCQB: TTSRF)

The QualityStocks Daily Newsletter would like to spotlightFathom Tartisan Nickel Corp. (CSE: TN) (OTCQB: TTSRF) .

Tartisan Nickel Corp., a Canadian mineral and battery materials exploration and mining development company, is looking to carve out a significant market share in the global nickel mining market

It looks to achieve this by banking on its flagship Kenbridge Nickel Project, which has shown significant potential, as evidenced in the recent preliminary Assessment Report ("PEA")

Its management has expressed its confidence in the value of the project and the potential to expand the mine's life, offering a rich source and modest capex compared to other deposits

Tartisan Nickel (CSE: TN) (OTCQB: TTSRF) (FSE: 8TA), a Canadian-based company specializing in mineral exploration and development, is announcing the acquisition of additional contiguous claims at the Kenbridge Nickel Project, Northwestern Ontario. Following the acquisition, the total property now consists of 93 contiguous patents, 153 single cell mining claims and 4 Mining Licenses, covering a total of 4,273 ha. According to the announcement, the patents and staked cells are owned 100% by Tartisan Nickel through wholly owned subsidiaries. The company also announced that Aspen Biological Ltd. staff have commenced the 2024 baseline study fieldwork, which includes completing the baseline aquatic and terrestrial fieldwork within the project footprint and access road options. The announcement noted that these studies, along with baseline data previously collected, will be used to develop baseline environmental reports to support provincial and federal reviews, approvals and permitting for advanced exploration and eventual mine development. "Aspen Biological can leverage its network of experienced resource professionals to pull together, as needed, multi-disciplinary teams to deliver upon project requirements and timelines in a cost-effective manner," said Mark Appleby, CEO of Tartisan Nickel.

To view the full press release, visit https://ibn.fm/mMUSh

Tartisan Nickel Corp. (CSE: TN) (OTCQB: TTSRF) is a Canadian mineral and battery metals exploration and mining development company. Tartisan’s flagship asset is the Kenbridge Nickel Project. Located in the Kenora Mining District, in the Province of Ontario, the Kenbridge Nickel Project is an advanced staged nickel deposit with a measured, indicated and inferred resource and has an existing 622-meter three compartment shaft.

As the world looks to utilize electric vehicles (EVs) in an effort to reduce air pollution, demand for EV battery metals is on the rise. Nickel is one of these in-demand battery metals, and there are few new, high grade development projects ready to meet this opportunity. Silver, zinc, copper and even lead are also part of this transformation in the EV sector. Tartisan Nickel Corp. is an advanced stage mining development company in a mining friendly jurisdiction. The company is headquartered in Toronto, Ontario, Canada.

Projects

The company’s flagship Kenbridge Nickel Project is in the north-central part of the Atikwa Lake area and the south-central part of the Fisher Lake Area in the Kenora Mining District, approximately 70 kilometers east-southeast of the Town of Kenora in northwestern Ontario. The property is accessible via gravel roads from paved Highway 71. The Kenbridge Nickel Project is covered by patented and unpatented mining claims totaling 10,150 acres.

Tartisan’s project portfolio also includes:

  • The Don Pancho Manganese Silver Zinc Project is in a prolific polymetallic mineral belt in central Peru with several operating mines in the area, including the world-class Iscaycruz and Yauliyacu polymetallic mines, operated by Glencore Xstrata PLC, which are located 50 kilometers to the north-northwest. Additionally, Travail Mining Corporation’s Santander silver-lead-zinc mine is located just nine kilometers to the east and Buenaventura’s silver-lead-zinc Uchucchacua mine, which produced 10 million ounces of silver in 2011, is located 63 kilometers to the north.
  • The Turtle Pond Nickel Copper Project includes 105 staked units covering approximately 5,440 acres in northwestern Ontario, approximately 40 kilometers south of the town of Dryden in the Turtle Pond and Ukik Lake area. The claims are located approximately 70 kilometers east of the company’s flagship Kenbridge Nickel Project.
  • The Sill Lake Lead Silver Project is located approximately 30 kilometers north-northeast of Sault Ste. Marie in Vankoughnet Township in the Sault Ste. Marie Mining District of Ontario. The Sill Lake Property comprises 57 contiguous mining claims totaling approximately 2,850 acres.

Market Opportunity

A report by Grand View Research, a market research and consulting company, estimated the global nickel mining market to be worth $50.4 billion in 2022 and projected the market will grow to a value of more than $84.04 billion by 2030, achieving a CAGR of 6.6% over the forecast period.

Nickel alloy is a component of EV, portable electronics and power tool batteries. In addition, nickel is one of the key raw materials of stainless steel. Hence, development in the EV industry and growth in stainless steel end-use industries such as construction, consumer durables and machinery and equipment contribute to the growth of the market.

According to the Nickel Institute, the industry association for the world’s nickel producers, over two-thirds of the world’s nickel is currently utilized in the production of stainless steel.

Management Team

D. Mark Appleby is President, CEO and Director of Tartisan Nickel. He has more than 37 years of experience in a variety of disciplines relating to investment banking, corporate finance and capital markets. His career began at Manulife in the equity and fixed income departments. He later joined First Boston Canada, where he reached the position of Vice President, Bond Trading. Subsequently, he has worked as an investment executive with Scotia Mcleod Inc. and is co-founder of The Atlantis Group. He also served as a Director of Guyana Goldfields Inc. for five years.

Omar Gonzalez is CFO of Tartisan Nickel. He has over 20 years of experience in audit and assurance in South America, as well as five years of public and private audit practice, financial analysis and corporate development in Canada. He has led many assurance and non-assurance engagements for companies in the energy, mining and natural resources, real estate, manufacturing and consumer business sectors. He is a Chartered Professional Accountant in Venezuela and holds a bachelor’s degree in accounting from the Universidad Santa María in Caracas.

Tartisan Nickel Corp. (OTCQB: TTSRF), closed Thursday's trading session at $0.184727, up 8.6629%, on 39,850 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.04685/$0.1905.

Recent News

Fathom Nickel Inc. (CSE: FNI) (FSE: 6Q5) (OTCQB: FNICF)

The QualityStocks Daily Newsletter would like to spotlightFathom Nickel Inc. (CSE: FNI) (FSE: 6Q5) (OTCQB: FNICF).

Fathom Nickel (CSE: FNI) (FSE: 6Q5) (OTCQB: FNICF), a Calgary-based Canadian natural resource development and exploration company, has sought to cater to the ongoing energy transition through the exploration and development of high-grade nickel sulfide developments. "Forecasts suggest that by 2040, electric vehicles (‘EVs') will comprise over 50% of annual passenger vehicles sales, as manufacturers and customers transition to cleaner forms of transportation in a bid to limit and curb the harmful emissions currently contributing to global warming. In turn, the surge in electric vehicle manufacturing and sales have significantly escalated the demand for crucial raw material inputs such as nickel within the electric vehicle supply chain," a recent article reads. "Nestled within the prolific Trans Hudson Corridor in Canada's Saskatchewan province, Fathom Nickel's two sites, namely the Albert Lake Project and the Gochager Lake Project, respectively, have played host to historic artisan mining operations, with Fathom Nickel now seeking to build upon the prior activity."

To view the full article, visit https://ibn.fm/RLfVp

Fathom Nickel Inc. (CSE: FNI) (FSE: 6Q5) (OTCQB: FNICF) is a Canadian natural resource development and exploration company that targets high-grade nickel sulfide discoveries for use in the rapidly growing global electric vehicle (EV) market. The company has a portfolio of two high-quality exploration projects located in the prolific Trans Hudson Corridor in Saskatchewan.

Led by a management team with more than 100 years of combined mining and exploration experience, Fathom believes in a continuing bright outlook for nickel and its increasing use in the manufacturing of batteries needed for energy storage in the high-growth renewable energy and EV industries. The company’s modern approach to exploration has yielded significant new nickel discoveries.

Fathom is headquartered in Calgary, Alberta.

Projects

The Albert Lake Project

The Albert Lake Project comprises 90,460 hectares of lands located in north-central Saskatchewan, with over 80,000 hectares currently unexplored. The project is host to the historic Rottenstone Mine, a high-grade, open pit nickel sulfide past producer that was active from 1965 to 1969 and yielded ~26,000 tonnes of 3.3% Ni, 1.8% Cu, and >9 g/t Pd-Pt+Au.

The geological setting of the Albert Lake Project is within the Trans Hudson Orogeny (Corridor), which is host to numerous world-class nickel mining camps including the Thompson Nickel Belt (currently operating with more than 5 billion pounds of nickel produced since 1959), Lynn Lake (past producer) and Raglan Nickel Belt (currently operating with more than 39,000 tons of nickel produced in 2020).

The project is fully permitted. Exploration plans for 2024 include drilling a high-priority target located approximately 2km south of the historic Rottenstone Mine along with drilling other high-priority targets. Additional soil geochemistry, surface geophysical programs and geological mapping and prospecting will be performed during the summer field season.

The Gochager Lake Project

The Gochager Lake Project in northern Saskatchewan, also in the prolific Trans Hudson Corridor, was recently expanded through the addition of the contiguous Watt’s Lake property and direct staking, bringing its total land area to 22,620 hectares.

The Gochager Lake property is host to a historic resource defined by drilling in 1966-1967 consisting of 4.2 M tons grading 0.29% Ni and 0.08% Cu. Recent drilling by Fathom has defined multiple very robust off-hole borehole electromagnetic (BHEM) responses in eight of nine holes drilled in 2023 and three historic drill holes probed. There is very strong evidence of multiple, high-grade nickel-copper-cobalt steeply oriented chutes within the historic Gochager Lake Deposit.

Prior to Fathom exploration in 2023 and since 1970, exploration at the property has been limited to small drill programs in 1989-1990 and 2018. Exploration plans for 2024 include expanded surface geophysical programs, drilling and continued BHEM surveys to expand tons and increase the grade of the historic Gochager Lake deposit. Summer exploration will consist of soil geochemistry, mapping, prospecting and additional surface geophysical programs focused on identifying other Gochager-like deposits within the current land package.

Market Opportunity

Nickel plays a crucial role in clean energy technologies, and that is expected to cause demand to well outstrip supply for the foreseeable future.

With an annual market value of around $35 billion, nickel demand is projected to rise due to its intensive use in lithium-ion batteries used to power EVs. However, new discoveries of nickel sulfide deposits (currently the most reliable source for battery-grade class 1 nickel) have been rare, which could constrain class 1 nickel supply in the coming years.

According to Deloitte’s global EV forecast, total EV sales will grow from 2.5 million in 2020 to 11.2 million in 2025, reaching 31.1 million by 2030 and representing approximately 32% of the total market share for new car sales. Over the next 10 years, the EV market is projected to see a CAGR of 29%, with increased demand for nickel expected to be comparable.

Management Team

Fathom Nickel has assembled a best-in-class leadership team consisting of highly qualified industry professionals with deep knowledge and understanding of the mineral exploration industry and capital markets.

Ian Fraser, P.Geo., is CEO, VP Exploration and Co-Founder of Fathom Nickel. He has more than 35 years of experience in mineral exploration, as well as managing and implementing exploration projects in Canada and internationally. His experience includes resource interpretation and development of the Casa Berardi Gold Mine and Komis Gold Mine, as well as the Cisneros Gold Mine in Colombia.

Doug Porter, CPA, CA, CBV, is President, CFO and Director of Fathom Nickel. He is a senior financial and accounting executive with specific emphasis in resource company management. His career includes positions with Elan Coal Ltd., Altitude Resources Ltd. and StimWrx Oilfield Services Ltd.

Fathom Nickel Inc. (OTCQB: FNICF), closed Thursday's trading session at $0.04775, up 3.1317%, on 85,292 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.0401/$0.2634.

Recent News

FingerMotion Inc. (NASDAQ: FNGR)

The QualityStocks Daily Newsletter would like to spotlight FingerMotion Inc. (NASDAQ: FNGR) .

One of the world's top semiconductor manufacturers has revealed that Chinese telecommunications company Huawei has fully replaced it with alternative suppliers. American semiconductor giant Qualcomm says embattled tech company Huawei doesn't need its advanced processors anymore and is now 100% reliant on other suppliers, a direct consequence of the ongoing trade war between China and the United States. With tensions between the two nations escalating over the past decade, the Trump administration took significant steps to expel Huawei from the American market due to reported security concerns. In the years since Huawei's expulsion from the U.S., lawmakers have strived to cripple the Chinese communications giant even further by limiting its access to the semiconductors it needs to build electronics such as mobile phones. Reports now indicate that the Pura 70 series uses a significant amount of Chinese-made components, a sign that Huawei's efforts to build an independent and resilient supply chain are paying off. Similarly, the U.S. is also trying to decouple itself from China in key industries such as green energy where Chinese companies have monopolized most of the supply chain and control minerals of strategic national importance to the U.S. The ongoing economic conflict between the U.S. and China could also force other companies such as FingerMotion Inc. (NASDAQ: FNGR) to consider suppliers outside the U.S. in order to ensure that their operations won't be compromised by future export bans instituted by the west.

FingerMotion Inc. (NASDAQ: FNGR) is an evolving technological company with core competencies in mobile payment and recharge platform solutions in China. FingerMotion is in the process of developing additional value-added technologies to market to users.

Founded in 2016, FingerMotion’s goal is to serve over a billion users in the Chinese market and expand its model to other regional markets. The company has offices in Hong Kong, Shanghai and New York City.

Current Offerings

FingerMotion is analyzing and transforming mobile data to improve the lifestyle of the public through technology and innovation. The company’s current offerings include:

  • Telecommunications Products and Services – FingerMotion’s proprietary universal exchange platform, ‘PigeonHole Integration System (PIS)’, offers seamless integration between telecom operators and online stores. The service platform’s offerings include top up and recharge, data plan, mobile phone, loyalty points redemption and subscription plans. The platform offers reliable and secure transactions, real-time reconciliation, simple integration for partners and efficient settlements.
  • SMS and MMS Services – The integrated platform is registered as FingerMotion’s IP in China and provides a robust back-end control panel for corporate partners to manage their own messaging settings. FingerMotion’s clients range from insurance to financial industries, ecommerce firms, airlines and more. The platform offers competitive pricing for partners and provides quick and efficient review to meet timely marketing initiatives.
  • Big Data Insights – FingerMotion brings Big Data-enabled insurance solutions through its Big Data Insights arm, Sapientus. The company’s strategic partnerships with the largest Chinese telecommunications giants allow access to uncover behavior insights through geolocation and mobile data usage. Its Big Data offerings include risk scoring, precise marketing, simplified underwriting and customized products.
  • Rich Communication Services (RCS) – FingerMotion’s RCS platform will be a proprietary business messaging solution that enables businesses and brands to communicate their services to customers via 5G infrastructure. The company expects its RCS platform to offer a better user experience, more efficiency and cost-effectiveness when compared to other solutions.

Telecommunications and Insurtech Markets

The global telecommunications market was valued at $1.74 trillion in 2019 and is expected to grow at a CAGR of 5% from 2020 to 2027. The steady increase is expected to be driven by the adoption of 5G and the increased popularity of Internet of Things (IoT) applications.

The Chinese telecom market was valued at $254.1 billion in 2017 and is also constantly expanding. The current Chinese telecom market is dominated by three mobile operators – China Mobile, China Unicom and China Telecom, which together are responsible for around 1.6 billion active subscribers (https://ibn.fm/zfwy9).

In addition, the insurtech (insurance technology) market was valued at $2.72 billion globally in 2020 and is expected to grow at a CAGR of 48.8% from 2021 to 2028. The large increase is attributed to the rising use of technology solutions for everyday activities like acquiring insurance coverage (https://ibn.fm/TGo7D).

Through its proprietary platforms and technologies, FingerMotion is uniquely positioned to capitalize on the telecom and insurtech markets’ growth and opportunities.

Management Team

Martin J. Shen is the Chief Executive Officer of FingerMotion Inc. He has over 15 years of experience in senior management roles within entrepreneurial startups and large multinational corporations. He has acquired a wide range of corporate management, financial oversight and operation administration expertise through these roles. In his most recent role, he founded Imperial Distributors (formerly known as AP Martin Pharmaceutical Supplies Ltd.), establishing the company as the preferred choice for distributional support to regional pharmacies throughout Western Canada. Before founding Imperial, Mr. Shen served as the Chief Operating Officer and Chief Financial Officer at Wales and Son Industrial (formerly Weir Minerals), a firm specializing in global delivery and support for mining slurry equipment. He began his career at PricewaterhouseCoopers in Vancouver, with work tours in the tax department in Singapore and the tax audit and advisory group in Hong Kong. Mr. Shen is a U.S. Certified Public Accountant and holds a Bachelor of Science from the University of British Columbia.

Lee Yew Hon is the company’s Chief Financial Officer. From 2006 until November 2020, he was the Chief Financial Officer of Cubinet Interactive Group of Companies, and he also took on the Chief Operating Officer role in 2011. During his tenure, he was instrumental in leading Cubinet and building teams across the Southeast Asia region, setting up financial processes within a short time. Mr. Lee spearheaded the growth of Cubinet to other regions, including Europe, the Middle East and Russia. He received his diploma from Tunku Abdul Rahman College in 1996. He is a Chartered Accountant, a member of the Malaysia Institute of Accountants (MIA) and an Associate Member of the Chartered Institute of Management Accountants, UK (ACMA).

Li Li is the Senior Vice President of FingerMotion. She recently served as Advisor to Shenzhen WuYiKa Technology Co. Ltd., a comprehensive service platform dedicated to online service distribution and payment. The company has become a fast and efficient provider of new media marketing solutions for the mobile internet. She has held high-level management positions with multiple industry names, including Hangzhou JiuYue Information Technology Co. Ltd. and Hangzhou LingXuan Information Technology. Ms. Li started her career in 2004, founding Shanghai ChuangYeZZ Network Technology Co. Ltd. and serving as its Vice President. With the close cooperation of local operators, the company launched SMS, MMS, WAP, mobile JAVA games, Hunan Satellite TV e-magazine and other wireless internet services to meet the rapid development of wireless internet and application requirements. She received her degree from Nanjing Academy of Engineering.

FingerMotion Inc. (FNGR), closed Thursday's trading session at $3.3, even for the day, on 373,392 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $1.28/$7.97.

Recent News

McEwen Mining Inc. (NYSE: MUX) (TSX: MUX)

The QualityStocks Daily Newsletter would like to spotlight McEwen Mining Inc. (NYSE: MUX) (TSX: MUX).

McEwen Mining (NYSE: MUX) (TSX: MUX), a gold and silver producer with operations in Nevada, Canada, Mexico and Argentina, owns 47.7% of McEwen Copper Inc., a well-funded, private company that owns 100% of the large, advanced-stage Los Azules copper project in Argentina. McEwen Copper today provided the assay results from the currently completed drill season at the Los Azules project. According to the company, initial interpretation of the assay results suggests that its infill drilling will result in an increase in Measured and Indicated resources and an overall mineral inventory within 5% of the PEA estimate. The announcement noted that testing for extensions beyond the planned pit has successfully encountered mineralization both to the north and to the south. More specifically, primary mineralization was intercepted (202.0 m of 0.20% Cu) over 400 meters north of last year's deep exploration hole, confirming its extension at depth a significant distance to the north. In addition, exploration south of the planned pit has intercepted the principal mineralized intrusive more than 700 meters south of previous drill intercepts. It indicates that prospective intrusives continue well to the south of the pit. Key highlights of the feasibility drilling program include Hole AZ23292 returning an intercept of 349 m of 0.77% Cu (approx. true thickness), with the Enriched zone portion of this hole extending over 346 meters and including an intercept of 232 m of 0.86% Cu. Moreover, Hole AZ23277 has an intercept of 382.5 m of 0.54% Cu (approx. true thickness). The Enriched zone portion of this hole extends over 306 meters with a grade of 0.61% Cu and includes an intercept of 74 m of 0.86% Cu.

To view the full press release, visit https://ibn.fm/rhees

McEwen Mining Inc. (NYSE: MUX) (TSX: MUX) is an asset rich diversified gold and silver producer in the Americas with a large exposure to copper through its subsidiary, McEwen Copper, owner of the Los Azules copper deposit in Argentina, believed to be the 8th largest undeveloped copper resource in the world.

Led by a management team with a track record of success, MUX owns and operates mines in some of the most prolific gold producing regions of the Americas. The company proactively took cost-saving measures months ago to lower expenses and increase production across its portfolio of gold assets, driving some production costs below industry averages. Gold and copper prices, already in an upswing, are forecast to enter an explosive uptrend over the next couple years. Drawing from its experience, McEwen Mining planned, prepared and laid the groundwork to capitalize on this emerging opportunity.

The company currently holds a Zacks Rank #1 (Strong Buy), placing it in the top 5% of over 4,000 stocks ranked by Zacks, based on trends in earnings estimate revisions and EPS surprises. Seldom is management so aligned with investors’ interests and committed to the company’s success. With a combined investment of over $220 million, CEO Rob McEwen holds a 17% ownership stake in McEwen Mining and a 13% ownership in McEwen Copper. Acclaimed in the mining industry, McEwen founded Goldcorp, where he increased the company’s market capitalization 160 times – from $50 million to over $8 billion. That same vision and tenacity led MUX in creating McEwen Copper.

For McEwen Mining shareholders, beyond the company’s exposure to gold upsurges, its 47.7% stake in McEwen Copper is expected to be a blockbuster, turbocharging MUX by creating the world’s next prolific copper unicorn.

McEwen Copper

With continuous industrial need, new critical demand for copper is rapidly emerging, increasingly driven by the green energy transition. The price of copper rose from a low of about $2 per pound in 2020 to over $4.60 per pound in May 2024, and strong demand is expected to intensify. A study by S&P Global, titled The Future of Copper: Will the Looming Supply Gap Short-circuit the Energy Transition?, projects global copper demand to nearly double over the next decade, from 25 million metric tons today to about 50 million metric tons by 2035. Based on current trends, S&P Global forecasts annual supply shortfalls to reach nearly 10 million metric tons in 2035.

McEwen Mining owns a 47.7% equity stake in McEwen Copper, the holder of a 100% interest in the Los Azules copper project in San Juan, Argentina, which is ranked the 8th largest undeveloped copper deposit in the world. Current copper resources at Los Azules are estimated at 10.9 billion pounds at a grade of 0.40% Cu (Indicated category) and an additional 26.7 billion pounds at a grade of 0.31% Cu (Inferred category). McEwen Copper also owns a copper exploration project in Nevada, USA, called Elder Creek.

In a 2023 Preliminary Economic Assessment (PEA), Los Azules was estimated to have a 27-year life, producing an average of 322 million lbs. of copper cathode annually, at a cash cost of $1.07 per lb. of copper, in the lowest quartile of the copper cost curve. The project could ultimately become an even larger mine with a longer life, since the extent of mineralization has not been fully assessed on the property.

The project’s 2023 PEA presents a distinctly different development strategy from a prior PEA published in 2017. By proposing a heap leach project using solvent extraction-electrowinning instead of the previously detailed mine with a conventional mill and flotation concentrator, McEwen Copper aims to decrease its environmental footprint and reduce permitting risk, albeit with a lower overall copper recovery, slightly higher unit costs and a delay in immediate cashflow due to extended leach cycles.

After securing a $25 million investment from mining giant Rio Tinto’s technology arm, Nuton LLC, McEwen Copper closed its non-brokered, private placement offering of $82 million in August 2022. Shortly after, in February 2023, Nuton agreed to invest an additional $30 million into McEwen Copper, and in October 2023, Nuton once again expanded its stake, investing an additional $10 million to bring its ownership position in McEwen Copper to 14.5%.

“We are extremely pleased to have Nuton’s strong continued participation in McEwen Copper,” Rob McEwen stated in a news release. “Together we are exploring new technologies that save energy, water, time and capital in the pursuit of delivering green copper to Argentina and the world, a product that will contribute to the electrification of transportation and the protection of our atmosphere.”

Also in February 2023, FCA Argentina S.A., a subsidiary of Stellantis N.V., one of the world’s leading automakers, invested ARS $30 billion in McEwen Copper. In October 2023, Stellantis invested an additional ARS $42 billion, bringing its current stake in McEwen Copper to 19.4%.

“We are delighted to have Stellantis as a partner in the future development of our Los Azules copper project,” Rob McEwen said of the investment. “Together, we share a vision to build a mine for the future based on regenerative principles that can achieve net-zero carbon emissions by 2038.”

Following the capital raise, McEwen Copper is well-funded to advance its Los Azules Project, with a Feasibility Study planned for Q1 2025. MUX strategically reduced its interest to increase its treasury, in order to reduce debt and fund the further development of its gold and silver assets.

Gold & Silver Projects

The Fox Complex

McEwen Mining owns a 100% stake in the Fox Complex in the heart of a prolific gold district in Timmins, Canada.

“When MUX bought the Fox Complex, in late 2017, it was a distressed asset with a history of high operating cost/oz. While it has taken longer than I expected, the cost to produce an ounce of gold is significantly lower,” CEO Rob McEwen stated in a news release.

McEwen Mining issued 2024 guidance for its cash cost/oz at the Fox Complex of $1,225-1,325 on annual production of 40,000-42,000 GEOs. Fox Complex produced 44,450 GEOs in 2023, which was within the company’s guidance range.

Located in one of the most prolific gold production areas in the world, along the Destor-Porcupine Fault Zone within the Abitibi Greenstone Belt, the Fox Complex includes the Black Fox mine and Froome mine which together have yielded over 1,000,000 ounces of gold to date. Also, the complex includes the Grey Fox and Stock deposits that have over 1,800,000 ounces in gold resources. The 2.7-billion-year-old Abitibi Greenstone Belt, formed by ancient volcanic activity, has proved to be one of the world’s richest and most abundant gold regions, with a total gold content currently estimated at over 300 million ounces.

In 2024, MUX commenced development of underground ramp access to the Stock orebodies at the Fox Complex. This development will become the primary source of feed following the completion of mining the Froome deposit in 2026. As part of the future mining sequence initiative, the company has already reported a 31% year-over-year increase of gold resources at Stock West and Stock Main (historical Stock Mine), with confirmation of good grading structures plunging to depth. It has also identified Stock East as a potential new near-term source of future revenue.

The Gold Bar Mine

McEwen Mining owns a 100% stake in the Gold Bar mine, located in an area well known for gold production, the southern Roberts Mountains of the Battle Mountain-Eureka-Cortez gold trend in Eureka County, Central Nevada. The Gold Bar mine is on the same geological structure, 25 miles south of Nevada Gold Mines, a Barrick-Newmont joint venture, part of the Cortez-Goldrush complex. This complex contains estimated reserves and resources of over 50 million gold ounces, with an annual production of 1,000,000 gold ounces.

Gold Bar had been mined between 1991 and 1994, producing 134,000 gold ounces. A new facility was built by MUX in 2019. Gold Bar accounted for 42,700 GEOs in 2023, within the company’s guidance for the year. For 2024, McEwen Mining issued guidance of 40,000-43,000 at a cash cost of $1,450-1,550. The first half of the year is expected to deliver higher production relative to the second half, due to a scheduled waste stripping phase in the Pick pit, in preparation for the 2025 mining program.

Notably, in April 2024, McEwen Mining announced its entry into a definitive agreement and plan of merger with Timberline Resources Corporation (TSX.V: TBR) (OTCQB: TLRS) in a transaction valued at roughly $18.8 million. The merger with Timberline is expected to augment McEwen’s existing portfolio of development and exploration projects in Nevada, leveraging synergies between Timberline’s projects and the Company’s Gold Bar mine.

El Gallo/Fenix

Project Fenix is the proposed redevelopment plan for McEwen Mining’s El Gallo Complex in Mexico. There is a long history of mining in this region. MUX began operating it as an open pit, heap leach mine in 2013, which produced 281,000 gold equivalent ounces at average cash cost of $655 per ounce. Due to the transition to deeper sulfide mineralization that is not amenable to heap leaching, mining activities ceased in the second quarter of 2018 and residual heap leaching followed until mid-2022. The redevelopment plan envisions constructing a mill at the existing mine site that will initially reprocess the existing heap leach material, then transition to open pit mining and processing of the sulphide mineralization. The company recently acquired a complete process plant on very advantageous terms that has considerably reduced the projected capital requirements for the project.

CEO Rob McEwen stated in a news release, “This acquisition has made Fenix more attractive to build and could provide a new long life mine for McEwen Mining.”

The initial development approach is to build a mill to reprocess the material on the heap leach pad and produce approximately 17,000 oz of gold annually for eight years. Construction of the Fenix project is expected to begin in the second half of 2024.

San José Mine

McEwen Mining is a 49% owner and non-operator of the San José gold and silver mine, located in Santa Cruz province, Argentina, encircling Newmont’s prolific Cerro Negro (approx. 300,000 gold ounces produced in 2023). This high-grade underground mine has been operating since 2007 and currently has an expected life of six years with a reserve grade of 296 gpt silver and 5.4 gpt gold.

Exploration is continuing to extend high-grade veins and discover new veins at the complex. San José’s drilling programs to define additional resources and reserves have a long history of success due to a high vein density, aided by good geophysical response from hidden veins.

Production guidance for 2024 for MUX’s 49% interest is 50,000-60,000 GEOs. As a minority shareholder in the mine, MUX equity accounts for its investment in San José, and receives 49% of the dividends from the mine’s free cash flow.

Market Outlook

Mining stocks suffered significant losses in the wake of the COVID-19 pandemic. However, this has turned, and many analysts now forecast a gold bull market in 2024 and beyond.

“The operating challenges we faced in recent years have severely damaged our credibility with our shareholders and the market. As a result, few investors have taken a close look recently at our assets,” Rob McEwen said in a news release. “If they did, I believe some would see the potential value that I see today… I believe there is considerable potential value in MUX, and that is a big reason why I have a personal financial commitment of $220 million in MUX and McEwen Copper.”

Management Team

Robert R. McEwen is Chairman, CEO and Chief Owner of McEwen Mining. He has been associated with the gold industry all his career, with his first 18 years in the investment industry and, since 1990, as CEO of several gold mining companies. He founded Goldcorp and took that company from a $50 million market capitalization to more than $8 billion. He owns 17% of McEwen Mining and is in complete alignment with investors – his investment in MUX and McEwen Copper is $220 million and he takes an annual salary of only $1. He was awarded the Order of Canada and the Queen Elizabeth’s Diamond Jubilee Award, was inducted into the Mining Hall of Fame, was named an Ernst and Young Entrepreneur of the Year and has Honorary Doctor of Law degrees from York University and Western University.

William Shaver is interim COO and a Director of McEwen Mining. He has decades of management and executive experience in mine design, construction and operations. He was a founder of Dynatec Corporation, which became one of the leading contracting and mine operating groups in North America. In 2013, he was recognized as Ernst and Young Entrepreneur of the Year. Most recently, he served as COO of INV Metals. He is a Professional Engineer with a B.Sc. in Mining Engineering from Queens University.

Perry Ing is interim CFO at McEwen Mining. He has 25 years of experience in the Canadian mining industry. Over the past 15 years, he has held positions as CFO of Mountain Province Diamonds, Kirkland Lake Gold and McEwen Mining. Prior to that, he worked at Barrick Gold and Goldcorp and started his career in the mining practice at PwC. He has a Bachelor of Commerce from the University of Toronto and is a Chartered Professional Accountant in Canada and Certified Professional Accountant in the U.S.

Adrian Blanco S. is the company’s Director of Operations for America and Mexico. He has extensive international experience in several industrial sectors and has held executive positions in Mexico, the United States, Peru and Argentina. He joined the McEwen Mining team in 2015 and has led a successful business transformation toward operational discipline, best business practices and financial profitability at subsidiaries Compañia Minera Pangea and McEwen Mining Nevada. He graduated from an Executive Management Program at IPADE and Harvard Business School.

Michael Meding is Vice President and General Manager of McEwen Copper. He has over 20 years of international experience, primarily with major mining companies such as Barrick Gold and Trafigura, including extensive experience with project development and operations in Argentina. While at Barrick Gold’s Veladero mine in Argentina, Mr. Meding played a key role in the turnaround, extension of the mine life and subsequent strategic partnering with Shandong Gold. He holds an MBA from Indiana University in Pennsylvania and an MBA from the Leipzig Graduate School of Management in Germany.

McEwen Mining Inc. (NYSE: MUX), closed Thursday's trading session at $10.6, off by 0.8419083%, on 632,466 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $5.92/$12.50.

Recent News

Nutriband Inc. (NASDAQ: NTRB)

The QualityStocks Daily Newsletter would like to spotlightFathom Nutriband Inc. (NASDAQ: NTRB) .

Nutriband (NASDAQ: NTRB), a developer of transdermal pharmaceutical solutions, has announced a new member of its board of directors. According to the announcement, Sergei Glinka, a seasoned and highly respected business executive, will serve on the board. An Estonian citizen, Glinka has served in several executive and board roles positions in large European companies, including Automecanica Skb Property Srl., GST Investments OU and TG Biochemicals Ltd. Glinka's expertise will support and facilitate new licensing and networking opportunities for Nutriband throughout Europe as the company works to expand its AVERSA(TM) technology, which is patented in 45 countries. The announcement noted that Glinka invested $4.5 million in Nutriband through the company's April $8.4 million private placement; the funds will be used to complete the FDA-approval process for the proprietary AVERSA technology. "We are thrilled to welcome Mr. Glinka to our board and believe his strategic insights and European market expertise will be invaluable as we continue to develop and expand our innovative suite of brands lead by our AVERSA technology," said Nutriband CEO Gareth Sheridan in the press release.

To view the full press release, visit https://ibn.fm/2Zvlr

Nutriband Inc. (NASDAQ: NTRB) is engaged in the development of a portfolio of transdermal pharmaceutical products. The company’s AVERSA™ technology can be incorporated into any transdermal patch and includes aversive agents to prevent abuse, diversion, misuse and accidental exposure to drugs with abuse potential, specifically opioids.

AVERSA technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, such as fentanyl, while making sure that these drugs remain accessible to patients who need them. The technology is covered by a broad intellectual property portfolio with patents granted in the United States, Europe, Japan, Korea, Russia, Canada, Mexico and Australia.

The company’s business model is to apply its transdermal technology to existing FDA-approved drugs with a goal of improving safety, efficacy and patient comfort while qualifying for a limited-development regulatory pathway that reduces the number of clinical trials required for approval of new drugs.

Nutriband has three subsidiaries, including 4P Therapeutics, its clinical and regulatory subsidiary; Pocono Pharmaceutical, a contract manufacturer for a wide range of clients; and Active Intelligence, a developer of sports recovery products. This ownership of manufacturing and clinical development capabilities drastically reduces costs for AVERSA and other technologies.

In April 2024, Nutriband announced that the company had been engaged by and received a first order from Fit For Life Group, a major brand license holder. A fully executed supplier agreement is expected to follow. Nutriband’s wholly owned Active Intelligence subsidiary will act as manufacturer.

The company is headquartered in Orlando, Florida.

Products

Nutriband’s lead product candidate is AVERSA Fentanyl, an abuse-deterrent fentanyl transdermal patch. The company announced in March 2024 that it will submit a New Drug Application to the U.S. Food and Drug Administration seeking approval to market AVERSA Fentanyl.

Nutriband has partnered with Kindeva Drug Delivery, a leading global contract development and manufacturing organization, to incorporate Nutriband’s AVERSA abuse-deterrent transdermal technology into Kindeva’s FDA-approved transdermal fentanyl patch system. Because Nutriband’s abuse-deterrent technology is incorporated into the fentanyl patch but is physically separate from and does not come in contact with the drug layer, the clinical trials typically needed to demonstrate safety and efficacy for a new drug formulation would not be required.

AVERSA Fentanyl has the potential to be the first and only abuse deterrent patch approved anywhere in the world. The company plans to seek an expedited review by the FDA, as has been granted for certain abuse-deterrent oral opioid products, which shortens the regulatory review period to six months from the conventional 10-month FDA review cycle for NDAs.

Nutriband’s AVERSA product development pipeline also includes abuse deterrent versions of currently approved and marketed transdermal patches containing buprenorphine, an opioid used to treat opioid use disorder, and methylphenidate, a central nervous system stimulant used in the treatment of attention deficit hyperactivity disorder (ADHD). Both are labeled with FDA-required warnings for the risk of abuse and misuse, as well as warnings against accidental exposure.

Market Opportunity

Nutriband cites a market analysis report from Boston-based Health Advances, a healthcare and life sciences consulting firm. According to the report, upon FDA approval, AVERSA Fentanyl has the potential to reach peak annual sales of $200 million in the U.S.

The company further states that, should non-abuse-deterrent transdermal fentanyl products lose FDA marketing approval, AVERSA Fentanyl would have greater pricing flexibility and would have the potential to generate more than $500 million in annual revenue.

Management Team

Gareth Sheridan is Co-Founder and CEO of Nutriband. He was Ireland’s ‘Young Entrepreneur of the Year’ in 2014 for establishing Nutriband. He has worked as a Business Mentor with 100 Minds, a social enterprise that brings together some of Ireland’s top college students and connects them with a cause to achieve large charitable goals. He received a B.Sc. in Business and Management from Dublin Institute of Technology.

Serguei Melnik is Co-Founder and President of Nutriband. He has been involved in general business consulting for companies in the U.S. financial markets and setting up legal and financial frameworks for operations of foreign companies in the U.S. He previously was the COO of Florida-based Asconi Corporation. He also was a lawyer in the Department of Foreign Affairs, JSC Bank “Inteprinzbanca,” in Chisinau, Moldova, and prior to that practiced law in Moldova. He is fluent in four languages.

Jeff Patrick, Pharm.D., is Chief Scientific Officer of Nutriband. He currently serves as Director of the Drug Development Institute at the Ohio State University Comprehensive Cancer Center. His prior roles included Global Vice President at Mallinckrodt Pharmaceuticals Inc.; and roles at Dyax, Myogen/Gilead, Actelion and Sanofi-Synthelabo Inc. He was a clinical pharmacist at the University of Tennessee Medical Center and a clinical assistant professor of pharmacy at the University of Tennessee College of Pharmacy.

Gerald Goodman is CFO of Nutriband. He is a certified public accountant with his own firm, Gerald Goodman CPA. He also practiced with Madsen & Associates, CPAs, and was a partner in the accounting firm of Wiener, Goodman & Company. He is also a director of Lifestyle Medical Network Inc., which provides management services to healthcare providers. He is a graduate of Pennsylvania State University, where he received a bachelor’s degree in accounting.

Nutriband Inc. (NASDAQ: NTRB), closed Thursday's trading session at $4.72, off by 6.5347%, on 139,746 volume. The average volume for the last 3 months is 50,858 and the stock's 52-week low/high is $1.53/$6.00.

Recent News

Torr Metals Inc. (TSX.V: TMET)

The QualityStocks Daily Newsletter would like to spotlightFathom Torr Metals Inc. (TSX.V: TMET) .

Torr Metals Inc. (TSX.V: TMET) is positioned amidst a growing urgency to discover and develop new gold and copper mines. The company is searching for the next big deposit across its 1,100 km of 100% owned highway-accessible projects located in some of Canada's most prolific mining jurisdictions. "Recent findings at the Kolos Copper-Gold Project defined a previously unknown trend to Cu-Au ± Mo mineralization with multiple potential undrilled porphyry centers stretching over 7 kilometers adjacent to Highway 5," reads a recent article discussing the company. "Gold has been treasured for its beauty and value for thousands of years. The shine on gold might not be dimming, but its supply is. Declining production from existing mines and dwindling reserves are creating a pressing need for new discoveries and development projects."

To view the full article, visit https://ibn.fm/zrhB9

Torr Metals Inc. (TSX.V: TMET) operates as a mineral exploration company focusing on the identification, acquisition, and advancement of mineral properties. With full 100% ownership of over 1,000 square kilometers of gold and copper projects strategically positioned in premier low-cost mining jurisdictions, Torr is poised for substantial returns across various promising regions.

The company’s extensive portfolio encompasses multiple district-scale projects, including the Filion Gold Project in northern Ontario, the Kolos Copper-Gold Project in south-central British Columbia, and the Latham Copper-Gold Project in northern British Columbia. These projects are all located in prolific mining regions with paved highway access, robust support infrastructure, and favorable geological conditions offering significant potential for new discoveries.

Headquartered in Vancouver, British Columbia, Torr Metals is ideally situated to leverage its expertise and resources for continued exploration and growth.

Projects

Kolos Copper-Gold Project

Situated within British Columbia’s prime copper-producing belt, the 140-square-kilometer Kolos Copper-Gold Project exhibits Nicola Belt geology similar to notable porphyry mines, including Copper Mountain and Highland Valley, respectively situated 106 kilometers to the south and 30 kilometers to the northwest.

With field operations based in the nearby city of Merritt and year-round access provided via Highway 5, the Kolos Project showcases substantial discovery upside potential with five defined large-scale copper-gold-molybdenum anomalies untested by drilling.

Torr Metals’ primary focus lies in unlocking the potential for major new discoveries at the Kolos Copper-Gold Project, with recent surface geochemical results marking a significant milestone positioning the company as a new key player in the region.

Filion Gold Project

The 261-square-kilometer Filion Project is situated within a largely unexplored greenstone belt where gold was initially discovered in the 1930s. With a comparable geological setting to regional orogenic gold deposits and multiple newly identified and undrilled gold trends in surficial geochemistry, the Filion Project holds significant district-scale exploration promise.

The Filion Project benefits from unparalleled infrastructure access, with direct drive-on access from the Trans-Canada Highway, as well as a regional railway and power grid four kilometers to the south. Additionally, the nearby town of Kapuskasing, with a population of 8,300, provides essential support services.

This strategic positioning ensures the Filion Project’s viability for cost-effective, year-round operations in an area poised for untapped discovery potential.

Latham Copper-Gold Project

Situated in British Columbia’s renowned Golden Triangle, the Latham Project spans a vast 689-square-kilometer district, offering immense potential for multiple major discoveries. Accessible year-round via Highway 37, just 20 kilometers south of the town of Dease Lake, the site is strategically located amidst established mining infrastructure, including the active Red Chris mine to the southeast and upcoming major porphyry projects at Schaft Creek and Galore Creek along-trend to the southwest.

Highlighted by the Gnat Pass copper-gold porphyry deposit dating back to the 1960s, the Latham Project presents a compelling opportunity for significant expansion and potential discovery. A non-compliant indicated resource at the Gnat Pass deposit includes 33 million tonnes at 0.39% copper, open beyond 200 meters vertical depth, alongside six drill-ready kilometer-scale copper-gold exploration targets.

Moreover, the Latham Project’s appeal corresponds to the region being an attractive destination for major asset acquisitions and takeovers. Recent transactions within a 40-kilometer radius include Newmont’s 2021 acquisition of the Saddle North copper-gold porphyry deposit for $311 million and Newcrest’s investment in the Red Chris copper-gold porphyry deposit in 2019 for $804 million, underscoring industry acknowledgment of the region’s potential.

Market Opportunity

The World Gold Council, the industry association for the world’s gold producers, estimated in 2023 that the physical financial gold market, which is made up of bars, coins, gold ETFs and central bank reserves, is worth nearly $5 trillion.

The council reports that gold mine production adds approximately 3,500 tons of the precious metal to the world’s supply annually, equivalent to about 2% growth. This historical scarcity and relatively slow production of new supply, as compared to other commodities, is a primary reason gold has retained its value for millennia, according to the council.

Likewise, a report from Acumen Research and Consulting, a global provider of market intelligence and consulting services, valued the global copper market at $304.1 billion in 2022 and forecast that it will reach a market size of $496.8 billion by 2032, growing at a CAGR of 5.1% over the forecast period.

The report identifies a growing demand for copper in the electronics industry, as well as an expanding copper supply due to increasing production from existing mines and the rising number of mine development projects in developing nations, as driving factors in the rising value of the copper market.

Management Team

Malcolm Dorsey, P.Geo., is President, CEO and Director of Torr Metals. He brings over a decade of expertise as a seasoned exploration geologist and project developer, having been pivotal in driving the success of numerous diverse projects across North, Central, and South America. His comprehensive background spans early-stage exploration through to resource development and project acquisitions. His academic credentials include an M.Sc. in Geology and Geophysics from the University of Calgary, where his research characterized the district-scale structural influences affecting copper and gold mineralizing events in western British Columbia. Prior to his current role, he served as Senior Geologist for Benchmark Metals, where his contributions were instrumental in advancing the company’s gold equivalent resource from approximately 80,000 ounces to a maiden resource estimate of 2.92 million ounces.

John Williamson, P. Geol., is Chairman and Director of Torr Metals. He is a mining executive and investor with more than 30 years of experience as a founder, promoter and leader in the formation, financing and operation of private and public companies with exploration and mining interests worldwide. On more than one occasion his team’s efforts have been recognized for excellence by being named to the TSX Venture 50. He holds a B.Sc. in Geology and is a registered Professional Geologist (P.Geol.) with the Association of Professional Engineers and Geoscientists (APEGA) and the Geological Association of Canada.

Torr Metals Inc. (TSX.V: TMET), closed Thursday's trading session at $30.185, off by 0.0662142%, on 28 volume. The average volume for the last 3 months is 158 and the stock's 52-week low/high is $24.01/$30.205.

Recent News

HealthLynked Corp. (OTCQB: HLYK)

The QualityStocks Daily Newsletter would like to spotlightFathom HealthLynked Corp. (OTCQB: HLYK) .

HealthLynked (OTCQB: HLYK), a trailblazer in healthcare technology, today announced its financial results for the first quarter ended March 31, 2024. During the quarter, the company's revenue reached $1.0 million, an 8% increase compared to the fourth quarter of 2023, underscoring HealthLynked's resilience and adaptability in managing transitions while maintaining operational efficiency. The announcement noted HealthLynked's continued strategic focus on cost control, which saw the company reduce operating expenses in the Health Services Division by 33%, SG&A expenses by 9%, and overall operating expenses by 22% in Q1 2024 compared to Q1 2023. The company reported a net loss from continuing operations of $1.39 million but remains financially resilient due to gains associated with the sale of ACO Health Partners. The sale generated $2.63 million in income last year. The announcement noted that the company aims to shift revenue streams from clinical operations to app-based services in 2024. "These results underscore our ability to optimize financial operations amid change. Strategic investments in technology and a provider network will ensure steady revenue growth in the coming quarters," said David Rosal, CFO of HealthLynked.

To view the full press release, visit https://ibn.fm/4VobH

HealthLynked Corp. (OTCQB: HLYK) is at the forefront of a transformative movement in healthcare, utilizing its extensive collection of health data to improve care for all. With a commitment to leveraging its advanced technology platforms, HealthLynked employs a sophisticated, cloud-based network that serves as a comprehensive repository for personal health data. This system not only simplifies the management and archiving of medical records but also enables the application of AI to deliver personalized healthcare insights. Through deep analysis of this data, HealthLynked’s AI capabilities help identify the root causes of diseases, tailor healthcare solutions to individual needs, and accelerate medical discoveries.

HealthLynked Corp. App

In addition to these capabilities, HealthLynked provides a user-friendly platform for booking healthcare appointments, similar to how OpenTable operates for restaurant reservations. This feature allows patients to conveniently book appointments with healthcare providers across the country, including options for telemedicine consultations, enhancing accessibility and efficiency in healthcare service delivery.

Strategically headquartered in Naples, Florida, HealthLynked operates through three primary divisions: Health Services, Digital Healthcare, and Medical Distribution. Each division supports the company’s mission to revolutionize patient care and health management. Positioned as a potential leader in healthcare AI, HealthLynked is dedicated to shaping the future of the industry over the next 20 years, driving significant advancements in healthcare accessibility and effectiveness through innovation and technology.

HealthLynked Corp. Reach

Strategic Initiatives and Operational Highlights

The company’s commitment to enhancing global health is evident in its dual goals: transforming healthcare through advanced technology and creating a patient-centric network that accelerates medical discoveries and the development of disease cures.

HealthLynked’s intellectual property portfolio is robust and strategically developed to enhance healthcare delivery and management. In March 2023, HealthLynked was granted a patent for a groundbreaking healthcare-specific wireless access point, known as the “Patient Access Hub.” This technology significantly improves the efficiency of healthcare practices by enabling real-time monitoring of patient flow within facilities. It intelligently determines patients waiting in exam rooms and calculates wait times, alongside other critical practice metrics. This system not only enhances patient experience by reducing unnecessary wait times but also optimizes resource allocation within healthcare settings.

Additionally, in October 2023, HealthLynked filed a patent application for its advanced AI program, ARI (Augmented Real-time Interface). ARI acts as a virtual doctor for patients, capable of performing medical intake, booking appointments, and providing personalized medical recommendations based on a patient’s medical history. By integrating these tasks, ARI streamlines the healthcare process, reducing the administrative burden on healthcare providers and ensuring that patients receive timely and tailored healthcare advice. This AI-driven interface enhances the accessibility and personalization of healthcare, embodying HealthLynked’s commitment to leveraging technology for better health outcomes. The company recently launched HealthLynked 3.2.0, an advanced version of its application, incorporating telemedicine, AI-driven personal healthcare guidance, and remote patient monitoring – setting a new standard in healthcare technology.

Market Position and Future Outlook

According to Facts and Figures Research, a research and consulting firm, the global market for patient-centric healthcare applications is projected to reach $41.6 billion by 2030, growing at a CAGR of 18.77% from 2022. HealthLynked’s offerings align perfectly with this expansive market opportunity, especially with increasing demands for digital health solutions and data management in healthcare.

HealthLynked’s strategic direction, spearheaded by its seasoned management team, is designed to leverage these market dynamics, enhancing patient engagement and healthcare efficiency on a global scale.

Management Team

Michael T. Dent, M.D., Founder, CEO, and Chairman, brings extensive experience from his foundational role at NeoGenomics and leadership in various healthcare and technology sector companies.

David Rosal, CFO, with previous senior roles at Teradata and McDonald’s Corporation, brings a wealth of expertise in financial and business integration strategies essential for growth and operational efficiency.

Chris Hall, CTO, with a strong background in global technology development from his time at Siemens and several patents to his name, is instrumental in driving the innovation and technological advancement at HealthLynked.

Bill Crupi, Operations Manager, has a proven track record in streamlining operations and enhancing productivity across multiple sectors within the healthcare industry. His expertise is crucial in maintaining the operational excellence that HealthLynked is known for.

Michael Paisan, Director of Investor Relations, leverages his extensive experience in finance and communications to enhance HealthLynked’s relationships with investors and stakeholders, ensuring transparent and effective communication of the company’s value and growth strategy.

Gagan Babber, Manager of Software Development, oversees the HealthLynked development teams based in the U.S. and India. With a robust background in engineering and software development, he plays a critical role in guiding the technological direction of HealthLynked’s products. His expertise in developing scalable, innovative software solutions is essential for driving the company’s technical initiatives forward and ensuring that HealthLynked stays at the forefront of digital healthcare technology.

HealthLynked Corp. (OTCQB: HLYK), closed Thursday's trading session at $0.05175, off by 4.9587%, on 133,286 volume. The average volume for the last 3 months is 53,111 and the stock's 52-week low/high is $0.033/$0.0999.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.